Try our mobile app

Published: 2021-08-09 16:34:59 ET
<<<  go to CBT company page
cbt-10q_20210630.htm
false 2021 Q3 0000016040 --09-30 us-gaap:OtherNonoperatingIncomeExpenseMember us-gaap:OtherNonoperatingIncomeExpenseMember P10Y P1Y 250000000 250000000 37000000 54000000 223000000 223000000 0.034 0.034 0000016040 2020-10-01 2021-06-30 xbrli:shares 0000016040 2021-08-04 iso4217:USD 0000016040 2021-04-01 2021-06-30 0000016040 2020-04-01 2020-06-30 0000016040 2019-10-01 2020-06-30 iso4217:USD xbrli:shares 0000016040 2021-06-30 0000016040 2020-09-30 0000016040 2019-09-30 0000016040 2020-06-30 0000016040 cbt:CommonStockNetOfTreasuryStockMember 2020-09-30 0000016040 us-gaap:RetainedEarningsMember 2020-09-30 0000016040 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0000016040 us-gaap:ParentMember 2020-09-30 0000016040 us-gaap:NoncontrollingInterestMember 2020-09-30 0000016040 us-gaap:RetainedEarningsMember 2020-10-01 2020-12-31 0000016040 us-gaap:ParentMember 2020-10-01 2020-12-31 0000016040 us-gaap:NoncontrollingInterestMember 2020-10-01 2020-12-31 0000016040 2020-10-01 2020-12-31 0000016040 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-10-01 2020-12-31 0000016040 cbt:CommonStockNetOfTreasuryStockMember 2020-10-01 2020-12-31 0000016040 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2020-12-31 0000016040 cbt:CommonStockNetOfTreasuryStockMember 2020-12-31 0000016040 us-gaap:RetainedEarningsMember 2020-12-31 0000016040 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000016040 us-gaap:ParentMember 2020-12-31 0000016040 us-gaap:NoncontrollingInterestMember 2020-12-31 0000016040 2020-12-31 0000016040 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000016040 us-gaap:ParentMember 2021-01-01 2021-03-31 0000016040 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0000016040 2021-01-01 2021-03-31 0000016040 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0000016040 cbt:CommonStockNetOfTreasuryStockMember 2021-01-01 2021-03-31 0000016040 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000016040 cbt:CommonStockNetOfTreasuryStockMember 2021-03-31 0000016040 us-gaap:RetainedEarningsMember 2021-03-31 0000016040 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0000016040 us-gaap:ParentMember 2021-03-31 0000016040 us-gaap:NoncontrollingInterestMember 2021-03-31 0000016040 2021-03-31 0000016040 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0000016040 us-gaap:ParentMember 2021-04-01 2021-06-30 0000016040 us-gaap:NoncontrollingInterestMember 2021-04-01 2021-06-30 0000016040 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0000016040 cbt:CommonStockNetOfTreasuryStockMember 2021-04-01 2021-06-30 0000016040 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0000016040 cbt:CommonStockNetOfTreasuryStockMember 2021-06-30 0000016040 us-gaap:RetainedEarningsMember 2021-06-30 0000016040 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0000016040 us-gaap:ParentMember 2021-06-30 0000016040 us-gaap:NoncontrollingInterestMember 2021-06-30 0000016040 cbt:CommonStockNetOfTreasuryStockMember 2019-09-30 0000016040 us-gaap:RetainedEarningsMember 2019-09-30 0000016040 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0000016040 us-gaap:ParentMember 2019-09-30 0000016040 us-gaap:NoncontrollingInterestMember 2019-09-30 0000016040 us-gaap:RetainedEarningsMember 2019-10-01 2019-12-31 0000016040 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-10-01 2019-12-31 0000016040 us-gaap:ParentMember 2019-10-01 2019-12-31 0000016040 us-gaap:NoncontrollingInterestMember 2019-10-01 2019-12-31 0000016040 2019-10-01 2019-12-31 0000016040 cbt:CommonStockNetOfTreasuryStockMember 2019-10-01 2019-12-31 0000016040 us-gaap:AdditionalPaidInCapitalMember 2019-10-01 2019-12-31 0000016040 cbt:CommonStockNetOfTreasuryStockMember 2019-12-31 0000016040 us-gaap:RetainedEarningsMember 2019-12-31 0000016040 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000016040 us-gaap:ParentMember 2019-12-31 0000016040 us-gaap:NoncontrollingInterestMember 2019-12-31 0000016040 2019-12-31 0000016040 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000016040 us-gaap:ParentMember 2020-01-01 2020-03-31 0000016040 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-03-31 0000016040 2020-01-01 2020-03-31 0000016040 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0000016040 cbt:CommonStockNetOfTreasuryStockMember 2020-01-01 2020-03-31 0000016040 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000016040 cbt:CommonStockNetOfTreasuryStockMember 2020-03-31 0000016040 us-gaap:RetainedEarningsMember 2020-03-31 0000016040 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000016040 us-gaap:ParentMember 2020-03-31 0000016040 us-gaap:NoncontrollingInterestMember 2020-03-31 0000016040 2020-03-31 0000016040 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0000016040 us-gaap:ParentMember 2020-04-01 2020-06-30 0000016040 us-gaap:NoncontrollingInterestMember 2020-04-01 2020-06-30 0000016040 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0000016040 cbt:CommonStockNetOfTreasuryStockMember 2020-04-01 2020-06-30 0000016040 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0000016040 cbt:CommonStockNetOfTreasuryStockMember 2020-06-30 0000016040 us-gaap:RetainedEarningsMember 2020-06-30 0000016040 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000016040 us-gaap:ParentMember 2020-06-30 0000016040 us-gaap:NoncontrollingInterestMember 2020-06-30 0000016040 cbt:ShenzhenSanshunNanoNewMaterialsCoLtdMember 2020-04-01 2020-04-01 0000016040 cbt:ShenzhenSanshunNanoNewMaterialsCoLtdMember 2020-06-01 2020-06-30 0000016040 cbt:ShenzhenSanshunNanoNewMaterialsCoLtdMember srt:MaximumMember 2020-04-01 0000016040 us-gaap:PensionPlansDefinedBenefitMember us-gaap:ForeignPlanMember 2021-04-01 2021-06-30 0000016040 us-gaap:PensionPlansDefinedBenefitMember us-gaap:ForeignPlanMember 2020-04-01 2020-06-30 0000016040 us-gaap:PensionPlansDefinedBenefitMember country:US 2020-04-01 2020-06-30 0000016040 us-gaap:PensionPlansDefinedBenefitMember us-gaap:ForeignPlanMember 2020-10-01 2021-06-30 0000016040 us-gaap:PensionPlansDefinedBenefitMember country:US 2019-10-01 2020-06-30 0000016040 us-gaap:PensionPlansDefinedBenefitMember us-gaap:ForeignPlanMember 2019-10-01 2020-06-30 0000016040 us-gaap:PensionPlansDefinedBenefitMember country:US 2020-10-01 2021-06-30 0000016040 srt:MaximumMember 2021-04-01 2021-06-30 0000016040 srt:MaximumMember 2020-04-01 2020-06-30 0000016040 country:US 2020-07-01 2020-09-30 0000016040 country:US 2020-10-01 2020-12-31 0000016040 cbt:ReinforcementMaterialsMember 2020-09-30 0000016040 cbt:PerformanceChemicalsMember 2020-09-30 0000016040 cbt:ReinforcementMaterialsMember 2020-10-01 2021-06-30 0000016040 cbt:PerformanceChemicalsMember 2020-10-01 2021-06-30 0000016040 cbt:ReinforcementMaterialsMember 2021-06-30 0000016040 cbt:PerformanceChemicalsMember 2021-06-30 0000016040 us-gaap:DevelopedTechnologyRightsMember 2021-06-30 0000016040 us-gaap:TrademarksMember 2021-06-30 0000016040 us-gaap:CustomerRelationshipsMember 2021-06-30 0000016040 us-gaap:DevelopedTechnologyRightsMember 2020-09-30 0000016040 us-gaap:TrademarksMember 2020-09-30 0000016040 us-gaap:CustomerRelationshipsMember 2020-09-30 0000016040 srt:MinimumMember 2020-10-01 2021-06-30 0000016040 srt:MaximumMember 2020-10-01 2021-06-30 0000016040 srt:WeightedAverageMember 2020-10-01 2021-06-30 0000016040 cbt:CostOfSalesSellingAndAdministrativeExpenseAndResearchAndTechnicalExpenseMember 2021-04-01 2021-06-30 0000016040 cbt:CostOfSalesSellingAndAdministrativeExpenseAndResearchAndTechnicalExpenseMember 2020-04-01 2020-06-30 0000016040 cbt:CostOfSalesSellingAndAdministrativeExpenseAndResearchAndTechnicalExpenseMember 2020-10-01 2021-06-30 0000016040 cbt:CostOfSalesSellingAndAdministrativeExpenseAndResearchAndTechnicalExpenseMember 2019-10-01 2020-06-30 0000016040 us-gaap:AccumulatedTranslationAdjustmentMember 2020-09-30 0000016040 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-09-30 0000016040 us-gaap:AccumulatedTranslationAdjustmentMember 2020-10-01 2020-12-31 0000016040 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-10-01 2020-12-31 0000016040 us-gaap:AccumulatedTranslationAdjustmentMember 2020-12-31 0000016040 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-12-31 0000016040 us-gaap:AccumulatedTranslationAdjustmentMember 2021-01-01 2021-03-31 0000016040 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-01-01 2021-03-31 0000016040 us-gaap:AccumulatedTranslationAdjustmentMember 2021-03-31 0000016040 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-03-31 0000016040 us-gaap:AccumulatedTranslationAdjustmentMember 2021-04-01 2021-06-30 0000016040 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-04-01 2021-06-30 0000016040 us-gaap:AccumulatedTranslationAdjustmentMember 2021-06-30 0000016040 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-06-30 0000016040 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-04-01 2021-06-30 0000016040 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-04-01 2020-06-30 0000016040 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-10-01 2021-06-30 0000016040 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-10-01 2020-06-30 0000016040 cbt:AccumulatedNetInvestmentHedgesGainLossExcludedFromEffectivenessTestingAndAmortizedToInterestExpenseMember 2020-10-01 2021-06-30 0000016040 cbt:AccumulatedNetInvestmentHedgesGainLossExcludedFromEffectivenessTestingAndAmortizedToInterestExpenseMember 2019-10-01 2020-06-30 0000016040 cbt:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossAndPriorServiceCostCreditMember 2021-04-01 2021-06-30 0000016040 cbt:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossAndPriorServiceCostCreditMember 2020-04-01 2020-06-30 0000016040 cbt:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossAndPriorServiceCostCreditMember 2020-10-01 2021-06-30 0000016040 cbt:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossAndPriorServiceCostCreditMember 2019-10-01 2020-06-30 0000016040 cbt:AccumulatedDefinedBenefitPlansAdjustmentNetSettlementChargeMember 2021-04-01 2021-06-30 0000016040 cbt:AccumulatedDefinedBenefitPlansAdjustmentNetSettlementChargeMember 2020-10-01 2021-06-30 0000016040 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-10-01 2021-06-30 0000016040 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-10-01 2020-06-30 0000016040 cbt:RespiratorLiabilitiesMember 2020-03-31 0000016040 cbt:RespiratorLiabilitiesMember cbt:SellingAndAdministrativeExpensesMember 2020-01-01 2020-03-31 0000016040 cbt:RespiratorLiabilitiesMember 2020-04-01 2020-06-30 0000016040 cbt:RespiratorLiabilitiesMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2020-10-01 2020-12-31 0000016040 cbt:RespiratorLiabilitiesMember 2020-10-01 2021-06-30 0000016040 cbt:RespiratorLiabilitiesMember 2021-06-30 0000016040 cbt:RespiratorLiabilitiesMember 2020-09-30 0000016040 cbt:BrazilIndirectTaxSettlementsMember 2021-04-01 2021-06-30 0000016040 cbt:BrazilIndirectTaxSettlementsMember cbt:NetSalesAndOtherOperatingRevenuesMember 2021-04-01 2021-06-30 0000016040 cbt:BrazilIndirectTaxSettlementsMember us-gaap:OtherNonoperatingIncomeExpenseMember 2021-04-01 2021-06-30 xbrli:pure 0000016040 us-gaap:InternalRevenueServiceIRSMember us-gaap:EarliestTaxYearMember 2020-10-01 2021-06-30 0000016040 us-gaap:InternalRevenueServiceIRSMember us-gaap:LatestTaxYearMember 2020-10-01 2021-06-30 0000016040 us-gaap:StateAndLocalJurisdictionMember us-gaap:EarliestTaxYearMember 2020-10-01 2021-06-30 0000016040 us-gaap:StateAndLocalJurisdictionMember us-gaap:LatestTaxYearMember 2020-10-01 2021-06-30 0000016040 us-gaap:ForeignCountryMember us-gaap:EarliestTaxYearMember 2020-10-01 2021-06-30 0000016040 us-gaap:ForeignCountryMember us-gaap:LatestTaxYearMember 2020-10-01 2021-06-30 0000016040 us-gaap:CostOfSalesMember 2021-04-01 2021-06-30 0000016040 us-gaap:CostOfSalesMember 2020-10-01 2021-06-30 0000016040 us-gaap:CostOfSalesMember 2019-10-01 2020-06-30 0000016040 cbt:SellingAndAdministrativeExpensesMember 2021-04-01 2021-06-30 0000016040 cbt:SellingAndAdministrativeExpensesMember 2020-04-01 2020-06-30 0000016040 cbt:SellingAndAdministrativeExpensesMember 2020-10-01 2021-06-30 0000016040 cbt:SellingAndAdministrativeExpensesMember 2019-10-01 2020-06-30 0000016040 cbt:ResearchAndTechnicalExpensesMember 2020-10-01 2021-06-30 0000016040 us-gaap:EmployeeSeveranceMember 2020-09-30 0000016040 us-gaap:EnvironmentalRemediationMember 2020-09-30 0000016040 cbt:NonCashAssetImpairmentMember 2020-10-01 2020-12-31 0000016040 us-gaap:OtherRestructuringMember 2020-10-01 2020-12-31 0000016040 us-gaap:EmployeeSeveranceMember 2020-10-01 2020-12-31 0000016040 us-gaap:EmployeeSeveranceMember 2020-12-31 0000016040 us-gaap:EnvironmentalRemediationMember 2020-12-31 0000016040 us-gaap:EmployeeSeveranceMember 2021-01-01 2021-03-31 0000016040 us-gaap:EmployeeSeveranceMember 2021-03-31 0000016040 us-gaap:EnvironmentalRemediationMember 2021-03-31 0000016040 us-gaap:EmployeeSeveranceMember 2021-04-01 2021-06-30 0000016040 us-gaap:OtherRestructuringMember 2021-04-01 2021-06-30 0000016040 us-gaap:EmployeeSeveranceMember 2021-06-30 0000016040 us-gaap:EnvironmentalRemediationMember 2021-06-30 0000016040 cbt:ReorganizationActionsMember 2020-10-01 2021-06-30 0000016040 cbt:ReorganizationActionsMember 2019-10-01 2020-09-30 0000016040 cbt:ReorganizationActionsMember 2019-10-01 2020-06-30 0000016040 cbt:ReorganizationActionsMember 2021-06-30 0000016040 cbt:ReorganizationActionsMember 2021-04-01 2021-06-30 0000016040 cbt:PurificationSolutionsTransformationPlanMember 2020-10-01 2021-06-30 0000016040 cbt:PurificationSolutionsTransformationPlanMember 2019-10-01 2020-09-30 0000016040 cbt:PurificationSolutionsTransformationPlanMember 2021-06-30 0000016040 us-gaap:ManufacturingFacilityMember cbt:PurificationSolutionsTransformationPlanMember 2021-06-30 0000016040 cbt:PrepaidExpensesAndOtherCurrentAssetsAccountsPayableAndAccruedLiabilitiesAndOtherAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignExchangeContractMember 2021-06-30 0000016040 cbt:PrepaidExpensesAndOtherCurrentAssetsAndOtherLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignExchangeContractMember 2020-09-30 0000016040 us-gaap:FairValueInputsLevel2Member 2021-06-30 0000016040 us-gaap:FairValueInputsLevel2Member 2020-09-30 0000016040 cbt:FixedRateDebtMember 2021-06-30 0000016040 cbt:FixedRateDebtMember 2020-09-30 0000016040 us-gaap:CrossCurrencyInterestRateContractMember cbt:ThreePointFourPercentageNotesDueTwoThousandAndTwentySixMember us-gaap:NetInvestmentHedgingMember 2021-06-30 iso4217:EUR 0000016040 us-gaap:CrossCurrencyInterestRateContractMember cbt:ThreePointFourPercentageNotesDueTwoThousandAndTwentySixMember us-gaap:NetInvestmentHedgingMember 2020-09-30 0000016040 us-gaap:CrossCurrencyInterestRateContractMember cbt:FixedRateDebtMember cbt:ThreePointFourPercentageNotesDueTwoThousandAndTwentySixMember us-gaap:NetInvestmentHedgingMember 2021-06-30 0000016040 us-gaap:CrossCurrencyInterestRateContractMember cbt:FixedRateDebtMember cbt:ThreePointFourPercentageNotesDueTwoThousandAndTwentySixMember us-gaap:NetInvestmentHedgingMember 2020-09-30 0000016040 us-gaap:NondesignatedMember us-gaap:ForwardContractsMember 2021-06-30 0000016040 us-gaap:NondesignatedMember us-gaap:ForwardContractsMember 2020-09-30 0000016040 us-gaap:NetInvestmentHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2021-06-30 0000016040 us-gaap:NetInvestmentHedgingMember us-gaap:CrossCurrencyInterestRateContractMember cbt:FixedRateDebtMember 2020-10-01 2021-06-30 0000016040 us-gaap:CrossCurrencyInterestRateContractMember 2021-06-30 0000016040 us-gaap:CrossCurrencyInterestRateContractMember 2020-09-30 0000016040 us-gaap:NetInvestmentHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2020-09-30 0000016040 us-gaap:CrossCurrencyInterestRateContractMember 2021-04-01 2021-06-30 0000016040 us-gaap:CrossCurrencyInterestRateContractMember 2020-04-01 2020-06-30 0000016040 us-gaap:CrossCurrencyInterestRateContractMember 2020-10-01 2021-06-30 0000016040 us-gaap:CrossCurrencyInterestRateContractMember 2019-10-01 2020-06-30 cbt:Segment 0000016040 cbt:PerformanceAdditivesMember us-gaap:OperatingSegmentsMember cbt:PerformanceChemicalsMember 2021-04-01 2021-06-30 0000016040 cbt:PerformanceAdditivesMember us-gaap:OperatingSegmentsMember cbt:PerformanceChemicalsMember 2020-04-01 2020-06-30 0000016040 cbt:PerformanceAdditivesMember us-gaap:OperatingSegmentsMember cbt:PerformanceChemicalsMember 2020-10-01 2021-06-30 0000016040 cbt:PerformanceAdditivesMember us-gaap:OperatingSegmentsMember cbt:PerformanceChemicalsMember 2019-10-01 2020-06-30 0000016040 cbt:FormulatedSolutionsMember us-gaap:OperatingSegmentsMember cbt:PerformanceChemicalsMember 2021-04-01 2021-06-30 0000016040 cbt:FormulatedSolutionsMember us-gaap:OperatingSegmentsMember cbt:PerformanceChemicalsMember 2020-04-01 2020-06-30 0000016040 cbt:FormulatedSolutionsMember us-gaap:OperatingSegmentsMember cbt:PerformanceChemicalsMember 2020-10-01 2021-06-30 0000016040 cbt:FormulatedSolutionsMember us-gaap:OperatingSegmentsMember cbt:PerformanceChemicalsMember 2019-10-01 2020-06-30 0000016040 us-gaap:OperatingSegmentsMember cbt:PerformanceChemicalsMember 2021-04-01 2021-06-30 0000016040 us-gaap:OperatingSegmentsMember cbt:PerformanceChemicalsMember 2020-04-01 2020-06-30 0000016040 us-gaap:OperatingSegmentsMember cbt:PerformanceChemicalsMember 2020-10-01 2021-06-30 0000016040 us-gaap:OperatingSegmentsMember cbt:PerformanceChemicalsMember 2019-10-01 2020-06-30 0000016040 us-gaap:OperatingSegmentsMember cbt:ReinforcementMaterialsMember 2021-04-01 2021-06-30 0000016040 us-gaap:OperatingSegmentsMember cbt:PurificationSolutionsMember 2021-04-01 2021-06-30 0000016040 us-gaap:OperatingSegmentsMember 2021-04-01 2021-06-30 0000016040 us-gaap:MaterialReconcilingItemsMember 2021-04-01 2021-06-30 0000016040 us-gaap:OperatingSegmentsMember cbt:ReinforcementMaterialsMember 2020-04-01 2020-06-30 0000016040 us-gaap:OperatingSegmentsMember cbt:PurificationSolutionsMember 2020-04-01 2020-06-30 0000016040 us-gaap:OperatingSegmentsMember 2020-04-01 2020-06-30 0000016040 us-gaap:MaterialReconcilingItemsMember 2020-04-01 2020-06-30 0000016040 us-gaap:OperatingSegmentsMember cbt:ReinforcementMaterialsMember 2020-10-01 2021-06-30 0000016040 us-gaap:OperatingSegmentsMember cbt:PurificationSolutionsMember 2020-10-01 2021-06-30 0000016040 us-gaap:OperatingSegmentsMember 2020-10-01 2021-06-30 0000016040 us-gaap:MaterialReconcilingItemsMember 2020-10-01 2021-06-30 0000016040 us-gaap:OperatingSegmentsMember cbt:ReinforcementMaterialsMember 2019-10-01 2020-06-30 0000016040 us-gaap:OperatingSegmentsMember cbt:PurificationSolutionsMember 2019-10-01 2020-06-30 0000016040 us-gaap:OperatingSegmentsMember 2019-10-01 2020-06-30 0000016040 us-gaap:MaterialReconcilingItemsMember 2019-10-01 2020-06-30 0000016040 us-gaap:MaterialReconcilingItemsMember us-gaap:ShippingAndHandlingMember 2021-04-01 2021-06-30 0000016040 us-gaap:MaterialReconcilingItemsMember us-gaap:ShippingAndHandlingMember 2020-04-01 2020-06-30 0000016040 us-gaap:MaterialReconcilingItemsMember us-gaap:ShippingAndHandlingMember 2020-10-01 2021-06-30 0000016040 us-gaap:MaterialReconcilingItemsMember us-gaap:ShippingAndHandlingMember 2019-10-01 2020-06-30 0000016040 us-gaap:MaterialReconcilingItemsMember us-gaap:ProductMember 2021-04-01 2021-06-30 0000016040 us-gaap:MaterialReconcilingItemsMember us-gaap:ProductMember 2020-04-01 2020-06-30 0000016040 us-gaap:MaterialReconcilingItemsMember us-gaap:ProductMember 2020-10-01 2021-06-30 0000016040 us-gaap:MaterialReconcilingItemsMember us-gaap:ProductMember 2019-10-01 2020-06-30 0000016040 us-gaap:MaterialReconcilingItemsMember cbt:OtherProductsAndServicesMember 2021-04-01 2021-06-30 0000016040 us-gaap:MaterialReconcilingItemsMember cbt:OtherProductsAndServicesMember 2020-04-01 2020-06-30 0000016040 us-gaap:MaterialReconcilingItemsMember cbt:OtherProductsAndServicesMember 2020-10-01 2021-06-30 0000016040 us-gaap:MaterialReconcilingItemsMember cbt:OtherProductsAndServicesMember 2019-10-01 2020-06-30 0000016040 us-gaap:CorporateNonSegmentMember 2021-04-01 2021-06-30 0000016040 us-gaap:CorporateNonSegmentMember 2020-10-01 2021-06-30 0000016040 us-gaap:CorporateNonSegmentMember 2019-10-01 2020-06-30 0000016040 us-gaap:CorporateNonSegmentMember 2020-04-01 2020-06-30 0000016040 us-gaap:CorporateNonSegmentMember cbt:SpecialtyFluidsMember 2019-10-01 2020-06-30 0000016040 cbt:ReinforcementMaterialsMember srt:AmericasMember 2021-04-01 2021-06-30 0000016040 cbt:PerformanceChemicalsMember srt:AmericasMember 2021-04-01 2021-06-30 0000016040 cbt:PurificationSolutionsMember srt:AmericasMember 2021-04-01 2021-06-30 0000016040 srt:AmericasMember 2021-04-01 2021-06-30 0000016040 cbt:ReinforcementMaterialsMember srt:AsiaPacificMember 2021-04-01 2021-06-30 0000016040 cbt:PerformanceChemicalsMember srt:AsiaPacificMember 2021-04-01 2021-06-30 0000016040 cbt:PurificationSolutionsMember srt:AsiaPacificMember 2021-04-01 2021-06-30 0000016040 srt:AsiaPacificMember 2021-04-01 2021-06-30 0000016040 cbt:ReinforcementMaterialsMember us-gaap:EMEAMember 2021-04-01 2021-06-30 0000016040 cbt:PerformanceChemicalsMember us-gaap:EMEAMember 2021-04-01 2021-06-30 0000016040 cbt:PurificationSolutionsMember us-gaap:EMEAMember 2021-04-01 2021-06-30 0000016040 us-gaap:EMEAMember 2021-04-01 2021-06-30 0000016040 srt:AmericasMember cbt:ReinforcementMaterialsMember 2020-04-01 2020-06-30 0000016040 srt:AmericasMember cbt:PerformanceChemicalsMember 2020-04-01 2020-06-30 0000016040 srt:AmericasMember cbt:PurificationSolutionsMember 2020-04-01 2020-06-30 0000016040 srt:AmericasMember 2020-04-01 2020-06-30 0000016040 srt:AsiaPacificMember cbt:ReinforcementMaterialsMember 2020-04-01 2020-06-30 0000016040 srt:AsiaPacificMember cbt:PerformanceChemicalsMember 2020-04-01 2020-06-30 0000016040 srt:AsiaPacificMember cbt:PurificationSolutionsMember 2020-04-01 2020-06-30 0000016040 srt:AsiaPacificMember 2020-04-01 2020-06-30 0000016040 us-gaap:EMEAMember cbt:ReinforcementMaterialsMember 2020-04-01 2020-06-30 0000016040 us-gaap:EMEAMember cbt:PerformanceChemicalsMember 2020-04-01 2020-06-30 0000016040 us-gaap:EMEAMember cbt:PurificationSolutionsMember 2020-04-01 2020-06-30 0000016040 us-gaap:EMEAMember 2020-04-01 2020-06-30 0000016040 srt:AmericasMember cbt:ReinforcementMaterialsMember 2020-10-01 2021-06-30 0000016040 srt:AmericasMember cbt:PerformanceChemicalsMember 2020-10-01 2021-06-30 0000016040 srt:AmericasMember cbt:PurificationSolutionsMember 2020-10-01 2021-06-30 0000016040 srt:AmericasMember 2020-10-01 2021-06-30 0000016040 srt:AsiaPacificMember cbt:ReinforcementMaterialsMember 2020-10-01 2021-06-30 0000016040 srt:AsiaPacificMember cbt:PerformanceChemicalsMember 2020-10-01 2021-06-30 0000016040 srt:AsiaPacificMember cbt:PurificationSolutionsMember 2020-10-01 2021-06-30 0000016040 srt:AsiaPacificMember 2020-10-01 2021-06-30 0000016040 us-gaap:EMEAMember cbt:ReinforcementMaterialsMember 2020-10-01 2021-06-30 0000016040 us-gaap:EMEAMember cbt:PerformanceChemicalsMember 2020-10-01 2021-06-30 0000016040 us-gaap:EMEAMember cbt:PurificationSolutionsMember 2020-10-01 2021-06-30 0000016040 us-gaap:EMEAMember 2020-10-01 2021-06-30 0000016040 srt:AmericasMember cbt:ReinforcementMaterialsMember 2019-10-01 2020-06-30 0000016040 srt:AmericasMember cbt:PerformanceChemicalsMember 2019-10-01 2020-06-30 0000016040 srt:AmericasMember cbt:PurificationSolutionsMember 2019-10-01 2020-06-30 0000016040 srt:AmericasMember 2019-10-01 2020-06-30 0000016040 srt:AsiaPacificMember cbt:ReinforcementMaterialsMember 2019-10-01 2020-06-30 0000016040 srt:AsiaPacificMember cbt:PerformanceChemicalsMember 2019-10-01 2020-06-30 0000016040 srt:AsiaPacificMember cbt:PurificationSolutionsMember 2019-10-01 2020-06-30 0000016040 srt:AsiaPacificMember 2019-10-01 2020-06-30 0000016040 us-gaap:EMEAMember cbt:ReinforcementMaterialsMember 2019-10-01 2020-06-30 0000016040 us-gaap:EMEAMember cbt:PerformanceChemicalsMember 2019-10-01 2020-06-30 0000016040 us-gaap:EMEAMember cbt:PurificationSolutionsMember 2019-10-01 2020-06-30 0000016040 us-gaap:EMEAMember 2019-10-01 2020-06-30 0000016040 us-gaap:SubsequentEventMember us-gaap:NaturalDisastersAndOtherCasualtyEventsMember srt:MinimumMember 2021-07-31 0000016040 us-gaap:SubsequentEventMember us-gaap:NaturalDisastersAndOtherCasualtyEventsMember srt:MaximumMember 2021-07-31 0000016040 us-gaap:SubsequentEventMember cbt:RevolvingCreditFacilityExpiryOctoberTwoThousandAndTwentyThreeMember 2021-07-31 0000016040 us-gaap:SubsequentEventMember cbt:RevolvingCreditFacilityExpiryAugustSixTwoThousandAndTwentySixMember 2021-08-06 0000016040 us-gaap:SubsequentEventMember cbt:RevolvingCreditFacilityExpiryOctoberTwoThousandAndTwentyThreeMember 2021-07-31 2021-07-31 0000016040 us-gaap:SubsequentEventMember cbt:RevolvingCreditFacilityExpiryAugustSixTwoThousandAndTwentySixMember 2021-08-06 2021-08-06 cbt:Option 0000016040 us-gaap:SubsequentEventMember cbt:RevolvingCreditFacilityExpiryAugustSixTwoThousandAndTwentySixMember srt:MaximumMember 2021-08-06

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2021

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

Commission file number 1-5667

 

Cabot Corporation

(Exact name of registrant as specified in its charter)

 

 

Delaware

04-2271897

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

 

Two Seaport Lane

Boston, Massachusetts

02210-2019

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (617) 345-0100

 

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

Title of each class

Trading symbol(s)

Name of each exchange on which registered

Common Stock, $1 par value per share

CBT

The New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

Accelerated filer

 

 

 

 

Non-accelerated filer

  

Smaller reporting company

 

 

 

 

Emerging growth company

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

The Company had 56,723,537 shares of common stock, $1.00 par value per share, outstanding as of August 4, 2021.

 

 

 

 


 

 

INDEX

 

Part I.

Financial Information

 

 

 

 

 

 

Item 1.

Financial Statements (unaudited)

 

 

 

Consolidated Statements of Operations

3

 

 

Consolidated Statements of Comprehensive Income (Loss)

4

 

 

Consolidated Balance Sheets

5

 

 

Consolidated Statements of Cash Flows

7

 

 

Consolidated Statements of Changes in Stockholders’ Equity

8

 

 

Notes to the Consolidated Financial Statements

10

 

 

 

 

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

24

 

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

34

 

Item 4.

Controls and Procedures

34

 

 

 

Part II.

Other Information

 

 

Item 5.

Other Information

35

 

Item 6.

Exhibits

36

 

2


 

 

Part I. Financial Information

Item 1.

Financial Statements

CABOT CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

UNAUDITED

 

 

 

Three Months Ended June 30

 

 

Nine Months Ended June 30

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

 

(In millions, except per share amounts)

 

Net sales and other operating revenues

 

$

917

 

 

$

518

 

 

$

2,505

 

 

$

1,955

 

Cost of sales

 

 

703

 

 

 

449

 

 

 

1,884

 

 

 

1,592

 

Gross profit

 

 

214

 

 

 

69

 

 

 

621

 

 

 

363

 

Selling and administrative expenses

 

 

68

 

 

 

52

 

 

 

200

 

 

 

230

 

Research and technical expenses

 

 

12

 

 

 

13

 

 

 

41

 

 

 

41

 

Specialty Fluids loss on sale and asset impairment charge

 

 

 

 

 

 

 

 

 

 

 

1

 

Income (loss) from operations

 

 

134

 

 

 

4

 

 

 

380

 

 

 

91

 

Interest and dividend income

 

 

2

 

 

 

1

 

 

 

6

 

 

 

7

 

Interest expense

 

 

(12

)

 

 

(13

)

 

 

(37

)

 

 

(41

)

Other income (expense)

 

 

(1

)

 

 

(3

)

 

 

(9

)

 

 

(6

)

Income (loss) before income taxes

   and equity in earnings of affiliated companies

 

 

123

 

 

 

(11

)

 

 

340

 

 

 

51

 

(Provision) benefit for income taxes

 

 

(30

)

 

 

5

 

 

 

(93

)

 

 

(9

)

Equity in earnings of affiliated companies, net of tax

 

 

2

 

 

 

1

 

 

 

3

 

 

 

2

 

Net income (loss)

 

 

95

 

 

 

(5

)

 

 

250

 

 

 

44

 

Net income (loss) attributable to noncontrolling interests, net

   of tax

 

 

9

 

 

 

1

 

 

 

29

 

 

 

10

 

Net income (loss) attributable to Cabot Corporation

 

$

86

 

 

$

(6

)

 

$

221

 

 

$

34

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average common shares outstanding:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

56.7

 

 

 

56.5

 

 

 

56.7

 

 

 

56.7

 

Diluted

 

 

57.0

 

 

 

56.5

 

 

 

56.8

 

 

 

56.7

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings (loss) per common share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

1.48

 

 

$

(0.12

)

 

$

3.85

 

 

$

0.59

 

Diluted

 

$

1.48

 

 

$

(0.12

)

 

$

3.84

 

 

$

0.59

 

 

The accompanying notes are an integral part of these consolidated financial statements.

3


 

CABOT CORPORATION

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

UNAUDITED

 

 

 

Three Months Ended June 30

 

 

Nine Months Ended June 30

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

 

(In millions)

 

Net income (loss)

 

$

95

 

 

$

(5

)

 

$

250

 

 

$

44

 

Other comprehensive income (loss), net of tax

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Foreign currency translation adjustment, net of tax

 

 

71

 

 

 

31

 

 

 

89

 

 

 

(4

)

Derivatives: net investment hedges

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(Gains) losses reclassified to interest expense, net of tax

 

 

(1

)

 

 

(1

)

 

 

(4

)

 

 

(3

)

(Gains) losses excluded from effectiveness testing and amortized to interest expense, net of tax

 

 

 

 

 

 

 

 

1

 

 

 

1

 

Pension and other postretirement benefit liability adjustments, net of tax

 

 

2

 

 

 

1

 

 

 

6

 

 

 

2

 

Other comprehensive income (loss)

 

 

72

 

 

 

31

 

 

 

92

 

 

 

(4

)

Comprehensive income (loss)

 

 

167

 

 

 

26

 

 

 

342

 

 

 

40

 

Net income (loss) attributable to noncontrolling interests, net

   of tax

 

 

9

 

 

 

1

 

 

 

29

 

 

 

10

 

Foreign currency translation adjustment attributable to

   noncontrolling interests, net of tax

 

 

3

 

 

 

2

 

 

 

8

 

 

 

2

 

Comprehensive income (loss) attributable to noncontrolling

   interests, net of tax

 

 

12

 

 

 

3

 

 

 

37

 

 

 

12

 

Comprehensive income (loss) attributable to Cabot Corporation

 

$

155

 

 

$

23

 

 

$

305

 

 

$

28

 

 

The accompanying notes are an integral part of these consolidated financial statements.

4


 

CABOT CORPORATION

CONSOLIDATED BALANCE SHEETS

ASSETS

UNAUDITED

 

 

 

June 30, 2021

 

 

September 30, 2020

 

 

 

(In millions)

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

173

 

 

$

151

 

Accounts and notes receivable, net of reserve for doubtful

   accounts of $3 and $2

 

 

633

 

 

 

418

 

Inventories:

 

 

 

 

 

 

 

 

Raw materials

 

 

141

 

 

 

82

 

Finished goods

 

 

293

 

 

 

225

 

Other

 

 

53

 

 

 

52

 

Total inventories

 

 

487

 

 

 

359

 

Prepaid expenses and other current assets

 

 

77

 

 

 

50

 

Total current assets

 

 

1,370

 

 

 

978

 

Property, plant and equipment, net

 

 

1,359

 

 

 

1,314

 

Goodwill

 

 

142

 

 

 

134

 

Equity affiliates

 

 

41

 

 

 

39

 

Intangible assets, net

 

 

103

 

 

 

103

 

Deferred income taxes

 

 

46

 

 

 

53

 

Other assets

 

 

164

 

 

 

160

 

Total assets

 

$

3,225

 

 

$

2,781

 

 

The accompanying notes are an integral part of these consolidated financial statements.

5


 

CABOT CORPORATION

CONSOLIDATED BALANCE SHEETS

LIABILITIES AND STOCKHOLDERS’ EQUITY

UNAUDITED

 

 

 

June 30, 2021

 

 

September 30, 2020

 

 

 

(In millions, except share

 

 

 

and per share amounts)

 

Current liabilities:

 

 

 

 

 

 

 

 

Short-term borrowings

 

$

59

 

 

$

14

 

Accounts payable and accrued liabilities

 

 

602

 

 

 

488

 

Income taxes payable

 

 

34

 

 

 

20

 

Current portion of long-term debt

 

 

9

 

 

 

7

 

Total current liabilities

 

 

704

 

 

 

529

 

Long-term debt

 

 

1,088

 

 

 

1,094

 

Deferred income taxes

 

 

58

 

 

 

58

 

Other liabilities

 

 

281

 

 

 

286

 

Contingencies (Note G)

 

 

 

 

 

 

 

 

Stockholders' equity:

 

 

 

 

 

 

 

 

Preferred stock:

 

 

 

 

 

 

 

 

Authorized: 2,000,000 shares of $1 par value

 

 

 

 

 

 

Issued and Outstanding: None and none

 

 

 

 

 

 

 

 

Common stock:

 

 

 

 

 

 

 

 

Authorized: 200,000,000 shares of $1 par value, Issued: 56,866,956 and 56,616,030 shares, Outstanding: 56,723,495 and 56,466,638 shares

 

 

57

 

 

 

57

 

Less cost of 143,461 and 149,392 shares of common treasury stock

 

 

(4

)

 

 

(4

)

Retained earnings

 

 

1,169

 

 

 

989

 

Accumulated other comprehensive income (loss)

 

 

(267

)

 

 

(351

)

Total Cabot Corporation stockholders' equity

 

 

955

 

 

 

691

 

Noncontrolling interests

 

 

139

 

 

 

123

 

Total stockholders' equity

 

 

1,094

 

 

 

814

 

Total liabilities and stockholders' equity

 

$

3,225

 

 

$

2,781

 

 

The accompanying notes are an integral part of these consolidated financial statements.

6


 

CABOT CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

UNAUDITED

 

 

 

Nine Months Ended June 30

 

 

 

2021

 

 

2020

 

 

 

(In millions)

 

Cash Flows from Operating Activities:

 

 

 

 

 

 

 

 

Net income (loss)

 

$

250

 

 

$

44

 

Adjustments to reconcile net income (loss) to cash provided by operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

117

 

 

 

117

 

Deferred tax provision (benefit)

 

 

4

 

 

 

(20

)

Employee benefit plan settlement

 

 

7

 

 

 

 

Equity in earnings of affiliated companies

 

 

(3

)

 

 

(2

)

Non-cash compensation

 

 

16

 

 

 

5

 

Other non-cash (income) expense

 

 

10

 

 

 

4

 

Cash dividends received from equity affiliates

 

 

2

 

 

 

1

 

Changes in assets and liabilities:

 

 

 

 

 

 

 

 

Accounts and notes receivable

 

 

(198

)

 

 

172

 

Inventories

 

 

(125

)

 

 

74

 

Prepaid expenses and other assets

 

 

(15

)

 

 

(25

)

Accounts payable and accrued liabilities

 

 

97

 

 

 

(68

)

Income taxes payable

 

 

12

 

 

 

(10

)

Other liabilities

 

 

(17

)

 

 

(14

)

Cash provided (used) by operating activities

 

 

157

 

 

 

278

 

Cash Flows from Investing Activities:

 

 

 

 

 

 

 

 

Additions to property, plant and equipment

 

 

(115

)

 

 

(162

)

Cash paid for acquisition of businesses, net of cash acquired of $— and $1

 

 

 

 

 

(92

)

Other

 

 

5

 

 

 

2

 

Cash provided (used) by investing activities

 

 

(110

)

 

 

(252

)

Cash Flows from Financing Activities:

 

 

 

 

 

 

 

 

Proceeds from issuance (repayments) of commercial paper, net

 

 

46

 

 

 

(20

)

Proceeds from long-term debt

 

 

150

 

 

 

444

 

Repayments of long-term debt

 

 

(167

)

 

 

(334

)

Purchases of common stock

 

 

(2

)

 

 

(44

)

Proceeds from sales of common stock

 

 

5

 

 

 

3

 

Cash dividends paid to noncontrolling interests

 

 

(20

)

 

 

(26

)

Cash dividends paid to common stockholders

 

 

(60

)

 

 

(60

)

Cash provided (used) by financing activities

 

 

(48

)

 

 

(37

)

Effects of exchange rate changes on cash

 

 

23

 

 

 

4

 

Increase (decrease) in cash and cash equivalents

 

 

22

 

 

 

(7

)

Cash and cash equivalents at beginning of period

 

 

151

 

 

 

169

 

Cash and cash equivalents at end of period

 

$

173

 

 

$

162

 

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

 

 

7


 

 

CABOT CORPORATION

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

UNAUDITED

 

 

 

Common Stock, Net of Treasury Stock

 

 

Additional

Paid-in

 

 

Retained

 

 

Accumulated Other Comprehensive

 

 

Total Cabot Corporation Stockholders’

 

 

Noncontrolling

 

 

Total Stockholders’

 

 

 

Shares

 

 

Cost

 

 

Capital

 

 

Earnings

 

 

Income (Loss)

 

 

Equity

 

 

Interests

 

 

Equity

 

 

 

(In millions, except share amounts)

 

Balance at September 30, 2020

 

 

56,467

 

 

$

53

 

 

$

 

 

$

989

 

 

$

(351

)

 

$

691

 

 

$

123

 

 

$

814

 

Net income (loss)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

60

 

 

 

 

 

 

 

60

 

 

 

10

 

 

 

70

 

Total other comprehensive income (loss)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

89

 

 

 

89

 

 

 

7

 

 

 

96

 

Cash dividends paid:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common stock, $0.35 per share

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(20

)

 

 

 

 

 

 

(20

)

 

 

 

 

 

 

(20

)

Cash dividends declared to noncontrolling interests

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1

)

 

 

(1

)

Issuance of stock under equity compensation plans

 

 

192

 

 

 

 

 

 

1

 

 

 

 

 

 

 

 

 

 

 

1

 

 

 

 

 

 

 

1

 

Amortization of share-based compensation

 

 

 

 

 

 

 

 

 

 

4

 

 

 

 

 

 

 

 

 

 

 

4

 

 

 

 

 

 

 

4

 

Purchase and retirement of common stock

 

 

(53

)

 

 

 

 

 

(2

)

 

 

 

 

 

 

 

 

 

 

(2

)

 

 

 

 

 

 

(2

)

Amount reclassified to retained earnings in excess of

     additional paid in capital

 

 

 

 

 

 

 

 

 

 

(3

)

 

 

3

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at December 31, 2020

 

 

56,606

 

 

$

53

 

 

$

 

 

$

1,032

 

 

$

(262

)

 

$

823

 

 

$

139

 

 

$

962

 

Net income (loss)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

75

 

 

 

 

 

 

 

75

 

 

 

10

 

 

 

85

 

Total other comprehensive income (loss)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(74

)

 

 

(74

)

 

 

(2

)

 

 

(76

)

Cash dividends paid:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common stock, $0.35 per share

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(20

)

 

 

 

 

 

 

(20

)

 

 

 

 

 

 

(20

)

Cash dividends declared to noncontrolling interests

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(11

)

 

 

(11

)

Issuance of stock under equity compensation plans

 

 

17

 

 

 

 

 

 

1

 

 

 

 

 

 

 

 

 

 

 

1

 

 

 

 

 

 

 

1

 

Amortization of share-based compensation

 

 

 

 

 

 

 

 

 

 

6

 

 

 

 

 

 

 

 

 

 

 

6

 

 

 

 

 

 

 

6

 

Purchase and retirement of common stock

 

 

(1

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amount reclassified to retained earnings in excess of

     additional paid in capital

 

 

 

 

 

 

 

 

 

 

(7

)

 

 

7

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at March 31, 2021

 

 

56,622

 

 

$

53

 

 

$

 

 

$

1,094

 

 

$

(336

)

 

$

811

 

 

$

136

 

 

$

947

 

Net income (loss)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

86

 

 

 

 

 

 

 

86

 

 

 

9

 

 

 

95

 

Total other comprehensive income (loss)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

69

 

 

 

69

 

 

 

3

 

 

 

72

 

Cash dividends paid:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common stock, $0.35 per share

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(20

)

 

 

 

 

 

 

(20

)

 

 

 

 

 

 

(20

)

Cash dividends declared to noncontrolling interests

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(9

)

 

 

(9

)

Issuance of stock under equity compensation plans

 

 

103

 

 

 

 

 

 

3

 

 

 

 

 

 

 

 

 

 

 

3

 

 

 

 

 

 

 

3

 

Amortization of share-based compensation

 

 

 

 

 

 

 

 

 

 

6

 

 

 

 

 

 

 

 

 

 

 

6

 

 

 

 

 

 

 

6

 

Purchase and retirement of common stock

 

 

(2

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amount reclassified to retained earnings in excess of

     additional paid in capital

 

 

 

 

 

 

 

 

 

 

(9

)

 

 

9

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at June 30, 2021

 

 

56,723

 

 

$

53

 

 

$

 

 

$

1,169

 

 

$

(267

)

 

$

955

 

 

$

139

 

 

$

1,094

 

The accompanying notes are an integral part of these consolidated financial statements.

8


 

CABOT CORPORATION

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

UNAUDITED

 

 

 

Common Stock, Net of Treasury Stock

 

 

Additional

Paid-in

 

 

Retained

 

 

Accumulated Other Comprehensive

 

 

Total Cabot Corporation Stockholders’

 

 

Noncontrolling

 

 

Total Stockholders’

 

 

 

Shares

 

 

Cost

 

 

Capital

 

 

Earnings

 

 

Income (Loss)

 

 

Equity

 

 

Interests

 

 

Equity

 

 

 

(In millions, except share amounts)

 

Balance at September 30, 2019

 

 

57,081

 

 

$

52

 

 

$

 

 

$

1,337

 

 

$

(391

)

 

$

998

 

 

$

136

 

 

$

1,134

 

Adoption of accounting standards

 

 

 

 

 

 

 

 

 

 

 

 

 

$

3

 

 

$

(3

)

 

 

 

 

 

 

 

 

 

 

Net income (loss)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

41

 

 

 

 

 

 

 

41

 

 

 

5

 

 

 

46

 

Total other comprehensive income (loss)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

40

 

 

 

40

 

 

 

3

 

 

 

43

 

Cash dividends paid:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common stock, $0.35 per share

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(20

)

 

 

 

 

 

 

(20

)

 

 

 

 

 

 

(20

)

Cash dividend declared to noncontrolling interests

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(19

)

 

 

(19

)

Issuance of stock under equity compensation plans

 

 

273

 

 

 

 

 

 

1

 

 

 

 

 

 

 

 

 

 

 

1

 

 

 

 

 

 

 

1

 

Amortization of share-based compensation

 

 

 

 

 

 

 

 

 

 

1

 

 

 

 

 

 

 

 

 

 

 

1

 

 

 

 

 

 

 

1

 

Purchase and retirement of common stock

 

 

(699

)

 

 

 

 

 

(2

)

 

 

(32

)

 

 

 

 

 

 

(34

)

 

 

 

 

 

 

(34

)

Balance at December 31, 2019

 

 

56,655

 

 

$

52

 

 

$

 

 

$

1,329

 

 

$

(354

)

 

$

1,027

 

 

$

125

 

 

$

1,152

 

Net income (loss)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1

)

 

 

 

 

 

 

(1

)

 

 

4

 

 

 

3

 

Total other comprehensive income (loss)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(75

)

 

 

(75

)

 

 

(3

)

 

 

(78

)

Cash dividends paid:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common stock, $0.35 per share

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(20

)

 

 

 

 

 

 

(20

)

 

 

 

 

 

 

(20

)

Cash dividend declared to noncontrolling interests

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(16

)

 

 

(16

)

Issuance of stock under equity compensation plans

 

 

30

 

 

 

 

 

 

2

 

 

 

 

 

 

 

 

 

 

 

2

 

 

 

 

 

 

 

2

 

Amortization of share-based compensation

 

 

 

 

 

 

 

 

 

 

2

 

 

 

 

 

 

 

 

 

 

 

2

 

 

 

 

 

 

 

2

 

Purchase and retirement of common stock

 

 

(241

)

 

 

 

 

 

(4

)

 

 

(6

)

 

 

 

 

 

 

(10

)

 

 

 

 

 

 

(10

)

Balance at March 31, 2020

 

 

56,444

 

 

$

52

 

 

$

 

 

$

1,302

 

 

$

(429

)

 

$

925

 

 

$

110

 

 

$

1,035

 

Net income (loss)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(6

)

 

 

 

 

 

 

(6

)

 

 

1

 

 

 

(5

)

Total other comprehensive income (loss)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

29

 

 

 

29

 

 

 

2

 

 

 

31

 

Cash dividends paid:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common stock, $0.35 per share

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(20

)

 

 

 

 

 

 

(20

)

 

 

 

 

 

 

(20

)

Issuance of stock under equity compensation plans

 

 

18

 

 

 

1

 

 

 

(1

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of share-based compensation

 

 

 

 

 

 

 

 

 

 

2

 

 

 

 

 

 

 

 

 

 

 

2

 

 

 

 

 

 

 

2

 

Purchase and retirement of common stock

 

 

(2

)

 

 

 

 

 

(1

)

 

 

1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at June 30, 2020

 

 

56,460

 

 

$

53

 

 

$

 

 

$

1,277

 

 

$

(400

)

 

$

930

 

 

$

113

 

 

$

1,043

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

9


 

 

CABOT CORPORATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2021

UNAUDITED

 

A. Basis of Presentation

The consolidated financial statements have been prepared in conformity with accounting policies generally accepted in the United States (“U.S.”) and include the accounts of Cabot Corporation (“Cabot” or the “Company”) and its wholly owned subsidiaries and majority-owned and controlled U.S. and non-U.S. subsidiaries. Additionally, Cabot considers consolidation of entities over which control is achieved through means other than voting rights. Intercompany transactions have been eliminated in consolidation.

The unaudited consolidated financial statements have been prepared in accordance with the requirements of Form 10-Q and consequently do not include all disclosures required by Form 10-K. Additional information may be obtained by referring to Cabot’s Annual Report on Form 10-K for its fiscal year ended September 30, 2020 (“2020 10-K”).

The financial information submitted herewith is unaudited and reflects all adjustments which are, in the opinion of management, necessary to provide a fair statement of the results for the interim periods ended June 30, 2021 and 2020. All such adjustments are of a normal recurring nature. The results for interim periods are not necessarily indicative of the results to be expected for the fiscal year.

 

B. Significant Accounting Policies

Recently Adopted Accounting Standards

 In June 2016, the FASB issued a new standard on measurement of credit losses. The standard introduces a new "expected loss" impairment model that applies to most financial assets measured at amortized cost and certain other instruments, including trade and other receivables and other financial assets. Entities are required to estimate expected credit losses over the life of financial assets and record an allowance against the assets’ amortized cost basis to present them at the amount expected to be collected. The Company adopted this standard on October 1, 2020. The adoption of this standard did not materially impact the Company’s consolidated financial statements.

Recent Accounting Pronouncements

In March 2020, the FASB issued a new standard on Reference Rate Reform, which provides temporary optional expedients and exceptions to the existing guidance on contract modifications and hedge accounting to ease the financial reporting burdens related to the expected market transition from the London Interbank Offered Rate ("LIBOR") and other interbank offered rates to alternative reference rates. The standard was effective upon issuance and may generally be applied through December 31, 2022 to any new or amended contracts, hedging relationships, and other transactions that reference LIBOR. The Company is currently evaluating the timing of adoption and the impact of the adoption of this standard on its consolidated financial statements.

 

In December 2019, the FASB issued a new standard Simplifying the Accounting for Income Taxes. The new guidance simplifies the accounting for income taxes by removing several exceptions in the current standard and adding guidance to reduce complexity in certain areas. The new standard is effective for fiscal years beginning after December 15, 2020 and early adoption is permitted. The Company expects to adopt the standard on October 1, 2021. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.

C. Acquisition

Shenzhen Sanshun Nano New Materials Co., Ltd

On April 1, 2020, the Company purchased Shenzhen Sanshun Nano New Materials Co., Ltd (SUSN), a leading carbon nanotube producer, for an estimated purchase price of $100 million, consisting of: (i) cash consideration of $84 million, net of $1 million acquired, (ii) contingent consideration of up to $3 million to be paid over the two-year period ending March 31, 2022 upon the satisfaction of certain milestones, and (iii) assumed debt of $13 million. The debt the Company assumed in the transaction was repaid in June 2020. The operating results of SUSN are included in the results of the Company's Performance Chemicals segment beginning in the third quarter of fiscal 2020.

 

10


 

 

D. Employee Benefit Plans

Net periodic defined benefit pension costs include the following:

 

 

 

Three Months Ended June 30

 

 

 

2021

 

 

2020

 

 

 

Pension Benefits

 

 

 

U.S.

 

 

Foreign

 

 

U.S.

 

 

Foreign

 

 

 

(In millions)

 

Service cost

 

$

 

 

$

1

 

 

$

 

 

$

1

 

Interest cost

 

 

 

 

 

 

 

 

1

 

 

 

1

 

Expected return on plan assets

 

 

 

 

 

(2

)

 

 

(1

)

 

 

(2

)

Amortization of prior service cost

 

 

 

 

 

2

 

 

 

 

 

 

 

Amortization of actuarial loss

 

 

 

 

 

1

 

 

 

 

 

 

1

 

Settlement charge

 

 

 

 

 

1

 

 

 

 

 

 

 

Net periodic benefit (credit) cost

 

$

 

 

$

3

 

 

$

 

 

$

1

 

 

 

 

Nine Months Ended June 30

 

 

 

2021

 

 

2020

 

 

 

Pension Benefits

 

 

 

U.S.

 

 

Foreign

 

 

U.S.

 

 

Foreign

 

 

 

(In millions)

 

Service cost

 

$

 

 

$

4

 

 

$

1

 

 

$

4

 

Interest cost

 

 

 

 

 

2

 

 

 

3

 

 

 

3

 

Expected return on plan assets

 

 

 

 

 

(7

)

 

 

(3

)

 

 

(7

)

Amortization of prior service cost

 

 

 

 

 

2

 

 

 

 

 

 

 

Amortization of actuarial loss

 

 

 

 

 

2

 

 

 

 

 

 

2

 

Settlement charge

 

 

6

 

 

 

1

 

 

 

 

 

 

 

Net periodic benefit (credit) cost

 

$

6

 

 

$

4

 

 

$

1

 

 

$

2

 

Other postretirement benefit costs were less than $1 million and $1 million for the three and nine months ended June 30, 2021, respectively. Other postretirement benefit costs were less than $1 million and $1 million for the three and nine months ended June 30, 2020, respectively.  

U.S. Cash Balance Plan Termination

In fiscal 2019, the Company’s Board of Directors approved a resolution to terminate the Company’s U.S. pension plan. In fiscal 2020 and 2021, the pension liability was settled through a combination of lump-sum payments and purchased annuities, neither of which required an additional cash contribution to the plan. In the fourth quarter of fiscal 2020, the Company recognized a settlement charge of $3 million related to lump-sum payments made to participants who elected this option, which was recorded in Other income (expense) in the Consolidated Statements of Operations. In the first quarter of fiscal 2021, the Company recognized an additional $6 million settlement charge in Other income (expense) related to the final asset transfers through purchased annuities.   

 

 

E. Goodwill and Intangible Assets

The carrying amount of goodwill attributable to each reportable segment with goodwill balances and the changes in those balances during the nine months ended June 30, 2021 are as follows:

 

 

Reinforcement

Materials

 

 

Performance

Chemicals

 

 

Total

 

 

 

(In millions)

 

Balance at September 30, 2020

 

$

46

 

 

$

88

 

 

$

134

 

Foreign currency impact

 

 

3

 

 

 

5

 

 

 

8

 

Balance at June 30, 2021

 

$

49

 

 

$

93

 

 

$

142

 

 

11


 

 

The following table provides information regarding the Company’s intangible assets:

 

 

 

June 30, 2021

 

 

September 30, 2020

 

 

 

Gross

Carrying

Value

 

 

Accumulated

Amortization

 

 

Net

Intangible

Assets

 

 

Gross

Carrying

Value

 

 

Accumulated

Amortization

 

 

Net

Intangible

Assets

 

 

 

(In millions)

 

Intangible assets with finite lives

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Developed technologies

 

$

63

 

 

$

(11

)

 

$

52

 

 

$

60

 

 

$

(8

)

 

$

52

 

Trademarks

 

 

11

 

 

 

(1

)

 

 

10

 

 

 

11

 

 

 

(1

)

 

 

10

 

Customer relationships

 

 

61

 

 

 

(20

)

 

 

41

 

 

 

56

 

 

 

(15

)

 

 

41

 

Total intangible assets

 

$

135

 

 

$

(32

)

 

$

103

 

 

$

127

 

 

$

(24

)

 

$

103

 

 

 

Intangible assets are amortized over their estimated useful lives, which range between ten and twenty-five years, with a weighted average amortization period of approximately eighteen years. Amortization expense for each of the three months ended June 30, 2021 and 2020 was $2 million and is included in Cost of sales, Selling and administrative expenses and Research and technical expenses in the Consolidated Statements of Operations. Amortization expense for the nine months ended June 30, 2021 and 2020 was $6 million and $5 million, respectively, and is included in Cost of sales, Selling and administrative expenses and Research and technical expenses in the Consolidated Statements of Operations. Total amortization expense is estimated to be approximately $8 million each year for the next five fiscal years.

 

F. Accumulated Other Comprehensive Income (Loss)

Comprehensive income combines net income (loss) and other comprehensive income items, which are reported as components of stockholders’ equity in the accompanying Consolidated Balance Sheets.

Changes in each component of AOCI, net of tax, were as follows:

 

 

 

Currency

Translation

Adjustment

 

 

Pension and Other

Postretirement

Benefit Liability

Adjustments

 

 

Total

 

 

 

(In millions)

 

Balance at September 30, 2020, attributable to Cabot Corporation

 

$

(307

)

 

$

(44

)

 

$

(351

)

Other comprehensive income (loss) before reclassifications

 

 

94

 

 

 

(1

)

 

 

93

 

Amounts reclassified from AOCI

 

 

(1

)

 

 

4

 

 

 

3

 

Less: Other comprehensive income (loss) attributable to

   noncontrolling interests

 

 

7

 

 

 

 

 

 

7

 

Balance at December 31, 2020, attributable to Cabot Corporation

 

 

(221

)

 

 

(41

)

 

 

(262

)

Other comprehensive income (loss) before reclassifications

 

 

(76

)

 

 

1

 

 

 

(75

)

Amounts reclassified from AOCI

 

 

(1

)

 

 

 

 

 

(1

)

Less: Other comprehensive income (loss) attributable to

   noncontrolling interests

 

 

(2

)

 

 

 

 

 

(2

)

Balance at March 31, 2021, attributable to Cabot Corporation

 

 

(296

)

 

 

(40

)

 

 

(336

)

Other comprehensive income (loss) before reclassifications

 

 

71

 

 

 

(3

)

 

 

68

 

Amounts reclassified from AOCI

 

 

(1

)

 

 

5

 

 

 

4

 

Less: Other comprehensive income (loss) attributable to

   noncontrolling interests

 

 

3

 

 

 

 

 

 

3

 

Balance at June 30, 2021, attributable to Cabot Corporation

 

$

(229

)

 

$

(38

)

 

$

(267

)

 

12


 

 

The amounts reclassified out of AOCI and into the Consolidated Statements of Operations in each of the three and nine months ended June 30, 2021 and 2020 were as follows:

 

 

 

Affected Line Item in the Consolidated

 

Three Months Ended June 30

 

 

Nine Months Ended June 30

 

 

 

Statements of Operations

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

 

 

 

(In millions)

 

 

 

 

 

 

 

 

 

Derivatives: net investment hedges

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(Gains) losses reclassified to interest

   expense

 

Interest expense (Note L)

 

$

(1

)

 

$

(2

)

 

$

(4

)

 

$

(4

)

(Gains) losses excluded from effectiveness testing and amortized to interest expense

 

Interest expense (Note L)

 

 

 

 

 

 

 

 

1

 

 

 

1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Pension and other postretirement

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of actuarial losses and prior service cost (credit)

 

Net Periodic Benefit Cost (Note D)

 

 

3

 

 

 

2

 

 

 

4

 

 

 

3

 

Settlement charge

 

Net Periodic Benefit Cost (Note D)

 

 

1

 

 

 

 

 

 

7

 

 

 

 

Total before tax

 

 

 

 

3

 

 

 

 

 

 

8

 

 

 

 

Tax impact

 

Provision (benefit) for income

   taxes

 

 

1

 

 

 

1

 

 

 

(2

)

 

 

1

 

Total after tax

 

 

 

$

4

 

 

$

1

 

 

$

6

 

 

$

1

 

 

 

 

G. Contingencies

Respirator Liabilities

Cabot has exposure in connection with a safety respiratory products business that a subsidiary acquired from American Optical Corporation (“AO”) in an April 1990 asset purchase transaction. The subsidiary manufactured respirators under the AO brand and disposed of that business in July 1995. In connection with its acquisition of the business, the subsidiary agreed, in certain circumstances, to assume a portion of AO’s liabilities, including costs of legal fees together with amounts paid in settlements and judgments, allocable to AO respiratory products used prior to the 1990 purchase by the Cabot subsidiary. In exchange for the subsidiary’s assumption of certain of AO’s respirator liabilities, AO agreed to provide to the subsidiary the benefits of: (i) AO’s insurance coverage for the period prior to the 1990 acquisition and (ii) a former owner’s indemnity of AO holding it harmless from any liability allocable to AO respiratory products used prior to May 1982. As more fully described in the 2020 10-K, the respirator liabilities generally involve claims for personal injury, including asbestosis, silicosis and coal worker’s pneumoconiosis, allegedly resulting from the use of respirators that are alleged to have been negligently designed and/or labeled. At no time did this respiratory product line represent a significant portion of the respirator market. In addition to Cabot’s subsidiary, other parties are responsible for significant portions of the costs of these respirator liabilities (as defined in the 2020 10-K, the “Payor Group”).

 On February 28, 2020, Cabot, with certain members of the Payor Group, entered into a settlement agreement resolving a large group of claims, including claims alleging serious injury, brought by coal workers in Kentucky and West Virginia represented by common legal counsel. The Company’s share of this liability was $65.2 million, and during the second quarter of fiscal 2020, Cabot recorded a charge of $50 million for this settlement, which was included in Selling and administrative expenses in the Consolidated Statements of Operations. The Company paid $32.6 million of the settlement during the third quarter of fiscal 2020 and the remaining $32.6 million in the first quarter of fiscal 2021.

Cabot has a reserve to cover its expected share of liabilities for pending and future respirator liability claims, which is included in Other liabilities and Accounts payable and accrued liabilities on the Consolidated Balance Sheets. The Company expects these liabilities to be incurred over a number of years. The reserve was $20 million and $24 million as of June 30, 2021 and September 30, 2020, respectively.

13


 

The Company’s current estimate of the cost of its share of pending and future respirator liability claims is based on facts and circumstances existing at this time, including the number and nature of the remaining claims. Developments that could affect the Company’s estimate include, but are not limited to, (i) changes in the number of pending and future claims, (ii) changes in the rate of dismissals without payment of pending claims, (iii) significant changes in the average cost of resolving claims, including potential settlements of groups of claims, (iv) significant changes in the legal costs of defending these claims, (v) changes in the nature of claims received or changes in our assessment of the viability of these claims, (vi) trial and appellate outcomes, (vii) changes in the law and procedure applicable to these claims, (viii) the financial viability of the parties that contribute to the payment of respirator claims, (ix) exhaustion or changes in the recoverability of the insurance coverage maintained by certain members of the Payor Group, or a change in the availability of the indemnity provided by a former owner of AO, (x) changes in the allocation of costs among the various parties paying legal and settlement costs, and (xi) a determination that the assumptions that were used to estimate Cabot’s share of liability are no longer reasonable. The Company cannot determine the impact of these potential developments on its current estimate of its share of liability for existing and future claims. Because reserves are limited to amounts that are probable and estimable as of a relevant measurement date, and there is inherent difficulty in projecting the impact of potential developments on Cabot’s share of liability for these existing and future claims, the actual amount of these liabilities for pending and future claims could be different than the reserved amount.

Brazil Indirect Tax Settlements

The Company previously filed claims with the Brazilian tax authorities challenging the calculation of certain indirect taxes related to local social contributions for the years 2012 through 2019.  During the third quarter of fiscal 2021, the Brazilian Federal Supreme Court rendered a final unappealable decision that clarified the methodology companies should use in the calculation.  As a result of this decision, the Company is entitled to recover credits and associated interest related to the historical periods for overpayment of these indirect taxes to be used to offset future Brazilian tax liabilities.  As such, the Company recorded a $12 million benefit during the third quarter of fiscal 2021 of which $9 million, related to the credit recovery was included in Net sales and other operating revenues and $3 million, related to interest income was included in Other income (expense) in the Consolidated Statement of Operations. 

Other Matters

The Company has various other lawsuits, claims and contingent liabilities arising in the ordinary course of its business and with respect to its divested businesses. The Company does not believe that any of these matters will have a material adverse effect on its financial position; however, litigation is inherently unpredictable. Cabot could incur judgments, enter into settlements or revise its expectations regarding the outcome of certain matters, and such developments could have a material impact on its results of operations in the period in which the amounts are accrued or its cash flows in the period in which the amounts are paid.

 

H. Income Tax

Effective Tax Rate

 

 

 

Three Months Ended June 30

 

 

Nine Months Ended June 30

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

 

(Dollars in millions)

 

(Provision) benefit for income taxes

 

$

(30

)

 

$

5

 

 

$

(93

)

 

$

(9

)

Effective tax rate

 

 

24

%

 

 

51

%

 

 

27

%

 

 

17

%

 

For the three and nine months ended June 30, 2021, the (Provision) benefit for income taxes included a net discrete tax expense of $1 million and $2 million, respectively. For the three and nine months ended June 30, 2020, the (Provision) benefit for income taxes included a net discrete tax benefit of $2 million and $14 million, respectively. The $14 million benefit was comprised of $8 million related to changes in uncertain tax positions and $6 million related to the impact of tax reform legislation in a foreign jurisdiction.

Income tax in Interim Periods

The Company records its tax provision or benefit on an interim basis using an estimated annual effective tax rate. This rate is applied to the current period ordinary income or loss to determine the income tax provision or benefit allocated to the interim period. The income tax effects of unusual or infrequent items are excluded from the estimated annual effective tax rate and are recognized in the impacted interim period. Losses from jurisdictions for which no benefit can be recognized are excluded from the overall computations of the estimated annual effective tax rate and a separate estimated annual effective tax rate is computed and applied to ordinary income or loss in the loss jurisdiction.

14


 

Valuation allowances are provided against the future tax benefits that arise from the deferred tax assets in jurisdictions for which no benefit can be recognized. The estimated annual effective tax rate may be significantly impacted by nondeductible expenses and the Company’s projected earnings mix by tax jurisdiction. Adjustments to the estimated annual effective income tax rate are recognized in the period when such estimates are revised.

Uncertainties

Cabot and certain subsidiaries are under audit in a number of jurisdictions. In addition, certain statutes of limitations are scheduled to expire in the near future. It is reasonably possible that a change in the unrecognized tax benefits may also occur within the next twelve months related to the settlement of one or more of these audits or the lapse of applicable statutes of limitations. However, an estimated range of the impact on the unrecognized tax benefits cannot be quantified at this time.

Cabot files U.S. federal and state and non-U.S. income tax returns in jurisdictions with varying statutes of limitations. The 2017 through 2019 tax years generally remain subject to examination by the IRS and various tax years from 2005 through 2019 remain subject to examination by the respective state tax authorities. In significant non-U.S. jurisdictions, various tax years from 2003 through 2020 remain subject to examination by their respective tax authorities.

During the three and nine months ended June 30, 2021, Cabot released uncertain tax positions of a nil amount and $1 million, respectively, due to the expiration of statutes of limitations in various jurisdictions. During the three and nine months ended June 30, 2020, Cabot released uncertain tax positions of $3 million and $11 million, respectively, due to audit settlements and the expiration of statutes of limitations in various jurisdictions.

 

15


 

 

I. Earnings Per Share

The following tables summarize the components of the basic and diluted earnings (loss) per common share (“EPS”) computations:

 

 

 

Three Months Ended June 30

 

 

Nine Months Ended June 30

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

 

(In millions, except per share amounts)

 

Basic EPS:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) attributable to Cabot

   Corporation

 

$

86

 

 

$

(6

)

 

$

221

 

 

$

34

 

Less: Dividends and dividend equivalents

   to participating securities

 

 

1

 

 

 

 

 

 

1

 

 

 

 

Less: Undistributed earnings allocated to

   participating securities(1)

 

 

1

 

 

 

 

 

 

2

 

 

 

 

Earnings (loss) allocated to common

   shareholders (numerator)

 

$

84

 

 

$

(6

)

 

$

218

 

 

$

34

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average common shares and

   participating securities outstanding

 

 

57.5

 

 

 

57.2

 

 

 

57.4

 

 

 

57.4

 

Less: Participating securities(1)

 

 

0.8

 

 

 

0.7

 

 

 

0.7

 

 

 

0.7

 

Adjusted weighted average common

   shares (denominator)

 

 

56.7

 

 

 

56.5

 

 

 

56.7

 

 

 

56.7

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings (loss) per common share - basic:

 

$

1.48

 

 

$

(0.12

)

 

$

3.85

 

 

$

0.59

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted EPS:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings (loss) allocated to common

   shareholders

 

$

84

 

 

$

(6

)

 

$

218

 

 

$

34

 

Plus: Earnings allocated to

   participating securities

 

 

1

 

 

 

 

 

 

2

 

 

 

 

Less: Adjusted earnings allocated to

   participating securities(2)

 

 

1

 

 

 

 

 

 

2

 

 

 

 

Earnings (loss) allocated to common

   shareholders (numerator)

 

$

84

 

 

$

(6

)

 

$

218

 

 

$

34

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted weighted average common

   shares outstanding

 

 

56.7

 

 

 

56.5

 

 

 

56.7

 

 

 

56.7

 

Effect of dilutive securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common shares issuable(3)

 

 

0.3

 

 

 

 

 

 

0.1

 

 

 

 

Adjusted weighted average common

   shares (denominator)

 

 

57.0

 

 

 

56.5

 

 

 

56.8

 

 

 

56.7

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings (loss) per common share - diluted:

 

$

1.48

 

 

$

(0.12

)

 

$

3.84

 

 

$

0.59

 

 

(1)

Participating securities consist of shares underlying all outstanding and achieved performance-based restricted stock units and all unvested time-based restricted stock units. The holders of these units are entitled to receive dividend equivalents payable in cash to the extent dividends are paid on the Company’s outstanding common stock and equal in value to the dividends that would have been paid in respect of the shares underlying such units.

16


 

Undistributed earnings are the earnings which remain after dividends declared during the period are assumed to be distributed to the common and participating shareholders. Undistributed earnings are allocated to common and participating shareholders on the same basis as dividend distributions. The calculation of undistributed earnings is as follows:

 

 

 

Three Months Ended June 30

 

 

Nine Months Ended June 30

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

 

(In millions)

 

Calculation of undistributed earnings (loss):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) attributable to Cabot Corporation

 

$

86

 

 

$

(6

)

 

$

221

 

 

$

34

 

Less: Dividends declared on common stock

 

 

20

 

 

 

20

 

 

 

60

 

 

 

60

 

Less: Dividends declared on participating

   securities

 

 

1

 

 

 

 

 

 

1

 

 

 

 

Undistributed earnings (loss)

 

$

65

 

 

$

(26

)

 

$

160

 

 

$

(26

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Allocation of undistributed earnings (loss):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Undistributed earnings (loss) allocated to

   common shareholders

 

$

64

 

 

$

(26

)

 

$

158

 

 

$

(26

)

Undistributed earnings allocated to

   participating shareholders

 

 

1

 

 

 

 

 

 

2

 

 

 

 

Undistributed earnings (loss)

 

$

65

 

 

$

(26

)

 

$

160

 

 

$

(26

)

 

(2)

Undistributed earnings are adjusted for the assumed distribution of dividends to the dilutive securities, which are described in (3) below, and then reallocated to participating securities.

(3)

Represents incremental shares of common stock from the (i) assumed exercise of stock options issued under Cabot’s equity incentive plans; and (ii) assumed issuance of shares to employees pursuant to the Company’s Deferred Compensation and Supplemental Retirement Plan. For the three and nine months ended June 30, 2021, 177,673 and 956,695 incremental shares of common stock were excluded from the calculation of diluted earnings per share because the inclusion of these shares would have been antidilutive. For the nine months ended June 30, 2020, 1,223,055 incremental shares of common stock were excluded from the calculation of diluted earnings per share because the inclusion of these shares would have been antidilutive. For the three months ended June 30, 2020, 1,853,427 incremental shares of common stock, which includes shares of participating securities as described in (1) above, were excluded from the calculation of diluted earnings per share because the inclusion of these shares would have been antidilutive due to the Company’s net loss position.

 

 

J. Restructuring

Cabot’s restructuring activities were recorded in the Consolidated Statements of Operations in the three and nine months ended June 30,2021 and 2020 as follows:

 

 

 

Three Months Ended June 30

 

 

Nine Months Ended June 30

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

 

(In millions)

 

Cost of sales

 

$

2

 

 

$

 

 

$

5

 

 

$

5

 

Selling and administrative expenses

 

 

2

 

 

 

3

 

 

 

2

 

 

 

11

 

Research and technical expenses

 

 

 

 

 

 

 

 

1

 

 

 

 

Total

 

$

4

 

 

$

3

 

 

$

8

 

 

$

16

 

 

17


 

 

Details of all restructuring activities and the related reserves during the nine months ended June 30, 2021 were as follows:

 

 

 

Severance

and Employee

Benefits

 

 

Environmental

Remediation

 

 

Non-cash Asset Impairment

 

 

Other

 

 

Total

 

 

 

(In millions)

 

Reserve at September 30, 2020

 

$

5

 

 

$

4

 

 

$

 

 

$

 

 

$

9

 

Charges (gain)

 

 

 

 

 

 

 

 

2

 

 

 

1

 

 

 

3

 

Cost charged against assets

 

 

 

 

 

 

 

 

(2

)

 

 

 

 

 

(2

)

Cash paid

 

 

(2

)

 

 

 

 

 

 

 

 

(1

)

 

 

(3

)

Reserve at December 31, 2020

 

 

3

 

 

 

4

 

 

 

 

 

 

 

 

 

7

 

Charges (gain)

 

 

1

 

 

 

 

 

 

 

 

 

 

 

 

1

 

Cash paid

 

 

(2

)

 

 

 

 

 

 

 

 

 

 

 

(2

)

Reserve at March 31, 2021

 

 

2

 

 

 

4

 

 

 

 

 

 

 

 

 

6

 

Charges (gain)

 

 

3

 

 

 

 

 

 

 

 

 

1

 

 

 

4

 

Cash paid

 

 

(1

)

 

 

 

 

 

 

 

 

(1

)

 

 

(2

)

Reserve at June 30, 2021

 

$

4

 

 

$

4

 

 

$

 

 

$

 

 

$

8

 

Cabot’s severance and employee benefit reserves and other closure related reserves are reflected in Accounts payable and accrued liabilities on the Company’s Consolidated Balance Sheets. Cabot’s environmental remediation reserves related to restructuring activities are reflected in Other liabilities on the Company’s Consolidated Balance Sheets.

Reorganization Actions

During fiscal 2020 and 2021, the Company has undertaken various actions to enable the Company to perform certain activities more effectively. These actions have primarily consisted of the reorganization of Cabot’s leadership structure, the creation of a Global Business Services function and other functional and operational efficiency initiatives. During the nine months ended June 30, 2020, the Company recorded charges of $15 million and paid cash of $10 million related to these activities. As of June 30, 2021, the Company had recorded total charges of $20 million, of which $17 million was recorded in fiscal 2020, primarily related to severance costs, and also had $3 million of accrued severance charges in the Consolidated Balance Sheets related to these actions. The Company expects to record additional restructuring charges of approximately $2 million throughout the rest of fiscal 2021 and $4 million thereafter, primarily related to severance and site demolition costs associated with the reorganization. As of June 30, 2021, the Company had paid a total of $17 million in cash, of which $13 million was paid in fiscal 2020, and expects to have future cash outlays of approximately $1 million in the remainder of fiscal 2021 and $8 million thereafter related to the reorganization.

Purification Solutions Transformation Plan

In December 2018, the Company initiated a transformation plan to improve the long‐term performance of the Purification Solutions segment. The purpose of the plan was to focus the business’s product portfolio, optimize its manufacturing assets, and streamline its organizational structure to support the new focus. As of June 30, 2021, the Company had recorded total charges of $15 million for this plan, of which $11 million was recorded in prior fiscal years, primarily related to severance costs, and also had $1 million of accrued severance and other charges in the Consolidated Balance Sheets related to this plan. The Company expects to record additional restructuring charges of $1 million throughout the rest of fiscal 2021 and $1 million thereafter primarily related to decommissioning costs associated with the business’s manufacturing facility in Marshall, Texas. As of June 30, 2021, the Company had paid a total of $11 million in cash for this plan, of which $9 million was paid in prior fiscal years, and expects to have future cash outlays of approximately $2 million in the remainder of fiscal 2021 and $1 million thereafter related to this plan.   

 

 

K. Financial Instruments and Fair Value Measurements

The FASB authoritative guidance on fair value measurements defines fair value, provides a framework for measuring fair value, and requires certain disclosures about fair value measurements. The required disclosures focus on the inputs used to measure fair value. The guidance establishes the following hierarchy for categorizing these inputs:

 

Level 1

 

 

Quoted market prices in active markets for identical assets or liabilities

 

 

 

 

 

Level 2

 

 

Significant other observable inputs (e.g., quoted prices for similar items in active markets, quoted prices for identical or similar items in markets that are not active, inputs other than quoted prices that are observable such as interest rate and yield curves, and market-corroborated inputs)

 

 

 

 

 

Level 3

 

 

Significant unobservable inputs

 

18


 

 

There were no transfers of financial assets or liabilities measured at fair value between Level 1 and Level 2 and there were no Level 3 investments during the first nine months of either fiscal 2021 or 2020.

At June 30, 2021 and September 30, 2020, Cabot had derivatives relating to foreign currency risks, including a net investment hedge and forward foreign currency contracts, carried at fair value. At June 30, 2021, the fair value of these derivatives was a net asset of $4 million and was included in Prepaid expenses and other current assets, Accounts payable and accrued liabilities, and Other assets on the Consolidated Balance Sheets. At September 30, 2020, the fair value of these derivatives was a net liability of $1 million and was included in Prepaid expenses and other current assets and Other liabilities on the Consolidated Balance Sheets. These derivatives are classified as Level 2 instruments within the fair value hierarchy as the fair value determination was based on observable inputs.

At each of June 30, 2021 and September 30, 2020, the fair value of guaranteed investment contracts, included in Other assets on the Consolidated Balance Sheets was $11 million. Guaranteed investment contracts were classified as Level 2 instruments within the fair value hierarchy as the fair value determination was based on other observable inputs.

At June 30, 2021 and September 30, 2020, the fair values of cash and cash equivalents, accounts and notes receivable, accounts payable and accrued liabilities, and short-term borrowings and variable rate debt approximated their carrying values due to the short-term nature of these instruments. The carrying value and fair value of the long-term fixed rate debt were $1.07 billion and $1.14 billion, respectively, as of June 30, 2021, and $1.08 billion and $1.18 billion, respectively, as of September 30, 2020. The fair values of Cabot’s fixed rate long-term debt are estimated based on comparable quoted market prices at the respective period ends. The carrying amounts of Cabot’s floating rate long-term debt and finance and operating lease obligations approximate their fair values. All such measurements are based on observable inputs and are classified as Level 2 within the fair value hierarchy. The valuation technique used is the discounted cash flow model.

 

 

L. Derivatives

Foreign Currency Risk Management

Cabot’s international operations are subject to certain risks, including currency exchange rate fluctuations and government actions. Cabot endeavors to match the currency in which debt is issued to the currency of the Company’s major, stable cash receipts. In some situations, Cabot has issued debt denominated in U.S. dollars and then entered into cross-currency swaps that exchange the dollar principal and interest payments into Euro-denominated principal and interest payments.

Additionally, the Company has foreign currency exposure arising from its net investments in foreign operations. Cabot may enter into cross-currency swaps to mitigate the impact of currency rate changes on the Company’s net investments.

The Company also has foreign currency exposure arising from the denomination of monetary assets and liabilities in foreign currencies other than the functional currency of a given subsidiary as well as the risk that currency fluctuations could affect the dollar value of future cash flows generated in foreign currencies. Accordingly, Cabot uses short-term forward contracts to minimize the exposure to foreign currency risk. In certain situations where the Company has forecasted purchases under a long-term commitment or forecasted sales denominated in a foreign currency, Cabot may enter into appropriate financial instruments in accordance with the Company’s risk management policy to hedge future cash flow exposures.

The following table provides details of the derivatives held as of June 30, 2021 and September 30, 2020 to manage foreign currency risk.

 

 

 

 

 

Notional Amount

 

 

Description

 

Borrowing

 

June 30, 2021

 

September 30, 2020

 

Hedge Designation

Cross-Currency Swaps

 

3.4% Notes

 

USD 250 million swapped to EUR 223 million

 

USD 250 million swapped to EUR 223 million

 

Net investment

Forward Foreign Currency Contracts (1)

 

N/A

 

USD 37 million

 

USD 54 million

 

No designation

 

(1)

19


 

As of June 30, 2021, Cabot’s forward foreign exchange contracts were denominated in Indonesian rupiah and Czech koruna. As of September 30, 2020, Cabot’s forward foreign exchange contracts were denominated in Canadian dollar, Indonesian rupiah and Czech koruna. At both June 30, 2021 and September 30, 2020 the fair value of these derivative instruments were a nominal amount.

Accounting for Derivative Instruments and Hedging Activities 

The Company has cross-currency swaps with a notional amount of $250 million, which are designated as hedges of its net investments in certain Euro-denominated subsidiaries. Cash settlements occur semi-annually on March 15th and September 15th for fixed rate interest payments and a cash exchange of the notional currency amount will occur at the end of the term in 2026. As of June 30, 2021, the fair value of these swaps was an asset of $4 million and was included in Prepaid expenses and other current assets and Other assets and the cumulative gain of $7 million was included in Currency Translation Adjustment within AOCI on the Consolidated Balance Sheets. As of September 30, 2020, the fair value of these swaps was a net liability of $1 million and was included in Prepaid expenses and other current assets and Other Liabilities, and the cumulative gain of $2 million was included in Currency Translation Adjustment within AOCI on the Consolidated Balance Sheets.

The following table summarizes the impact of the cross-currency swaps to AOCI and the Consolidated Statements of Operations:

 

 

 

Three Months Ended June 30

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Description

 

Gain/(Loss) Recognized in AOCI

 

 

(Gain)/Loss Reclassified from AOCI into Interest Expense in the Consolidated Statements of Operations

 

 

(Gain)/Loss Recognized in Interest Expense in the Consolidated Statements of Operations (Amount Excluded from Effectiveness Testing)

 

 

 

(In millions)

 

Cross-currency swaps

 

$

25

 

 

$

1

 

 

$

(1

)

 

$

(2

)

 

$

 

 

$

 

 

 

 

 

Nine Months Ended June 30

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Description

 

Gain/(Loss) Recognized in AOCI

 

 

(Gain)/Loss Reclassified from AOCI into Interest Expense in the Consolidated Statements of Operations

 

 

(Gain)/Loss Recognized in Interest Expense in the Consolidated Statements of Operations (Amount Excluded from Effectiveness Testing)

 

 

 

(In millions)

 

Cross-currency swaps

 

$

7

 

 

$

11

 

 

$

(4

)

 

$

(4

)

 

$

1

 

 

$

1

 

 

 

 

M. Financial Information by Segment

The Company identifies a business as an operating segment if: (i) it engages in business activities from which it may earn revenues and incur expenses; (ii) its operating results are regularly reviewed by the Chief Operating Decision Maker (“CODM”), who is Cabot’s President and Chief Executive Officer, to make decisions about resources to be allocated to the segment and assess its performance; and (iii) it has available discrete financial information. The Company has determined that all of its businesses are operating segments. The CODM reviews financial information at the operating segment level to allocate resources and to assess the operating results and financial performance for each operating segment. Operating segments are aggregated into a reportable segment if the operating segments are determined to have similar economic characteristics and if the operating segments are similar in the following areas: (i) nature of products and services; (ii) nature of production processes; (iii) type or class of customer for their products and services; (iv) methods used to distribute the products or provide services; and (v) if applicable, the nature of the regulatory environment.

The Company has three reportable segments: Reinforcement Materials, Performance Chemicals, and Purification Solutions.

The Reinforcement Materials segment consists of the rubber blacks and elastomer composites product lines.

The Performance Chemicals segment combines the specialty carbons, fumed metal oxides and aerogel product lines into the Performance Additives business, and combines the specialty compounds and inkjet colorants product lines into the Formulated Solutions business. These businesses are similar in terms of economic characteristics, nature of products, processes, customer class and product distribution methods, and, therefore, have been aggregated into one reportable segment. The net sales from each of these businesses for the three and nine months ended June 30, 2021 and 2020 were as follows:

 

 

 

Three Months Ended June 30

 

 

Nine Months Ended June 30

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

 

(In millions)

 

Performance Additives

 

$

208

 

 

$

151

 

 

$

595

 

 

$

489

 

Formulated Solutions

 

 

95

 

 

 

69

 

 

 

269

 

 

 

218

 

Total Performance Chemicals

 

$

303

 

 

$

220

 

 

$

864

 

 

$

707

 

 

20


 

 

The Purification Solutions segment consists of the Company’s activated carbon business.

Income (loss) before income taxes (“Segment EBIT”) is presented for each reportable segment in the table below. Segment EBIT excludes Interest expense, general unallocated income (expense), unallocated corporate costs, and certain items, meaning items management does not consider representative of on-going operating segment results. In addition, Segment EBIT includes Equity in earnings of affiliated companies, net of tax, the full operating results of a contractual joint venture in Purification Solutions, royalties, Net income attributable to noncontrolling interests, net of tax, and discounting charges for certain Notes receivable.

Financial information by reportable segment is as follows:

 

 

 

Reinforcement

Materials

 

 

Performance

Chemicals

 

 

Purification

Solutions

 

 

Segment

Total

 

 

Unallocated

and Other(1)

 

 

Consolidated

Total

 

 

 

(In millions)

 

Three Months Ended June 30, 2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenues from external customers(2)

 

$

479

 

 

$

303

 

 

$

69

 

 

$

851

 

 

$

66

 

 

$

917

 

Income (loss) before income taxes(3)

 

$

85

 

 

$

54

 

 

$

6

 

 

$

145

 

 

$

(22

)

 

$

123

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended June 30, 2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenues from external customers(2)

 

$

197

 

 

$

220

 

 

$

63

 

 

$

480

 

 

$

38

 

 

$

518

 

Income (loss) before income taxes(3)

 

$

(5

)

 

$

21

 

 

$

2

 

 

$

18

 

 

$

(29

)

 

$

(11

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended June 30, 2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenues from external customers(2)

 

$

1,288

 

 

$

864

 

 

$

191

 

 

$

2,343

 

 

$

162

 

 

$

2,505

 

Income (loss) before income taxes(3)

 

$

262

 

 

$

166

 

 

$

6

 

 

$

434

 

 

$

(94

)

 

$

340

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended June 30, 2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenues from external customers(2)

 

$

931

 

 

$

707

 

 

$

186

 

 

$

1,824

 

 

$

131

 

 

$

1,955

 

Income (loss) before income taxes(3)

 

$

103

 

 

$

93

 

 

$

3

 

 

$

199

 

 

$

(148

)

 

$

51

 

 

(1)

Unallocated and Other includes certain items and eliminations necessary to reflect management’s reporting of operating segment results. These items are reflective of the segment reporting presented to the CODM.

(2)

Consolidated Total Revenues from external customers reconciles to Net sales and other operating revenues on the Consolidated Statements of Operations. Revenues from external customers that are categorized as Unallocated and Other reflects royalties, external shipping and handling fees, the impact of unearned revenue, the removal of 100% of the sales of an equity method affiliate, discounting charges for certain Notes receivable, by-product revenue, and indirect tax settlement credits. Details are provided in the table below:

 

 

 

Three Months Ended June 30

 

 

Nine Months Ended June 30

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

 

(In millions)

 

Shipping and handling fees

 

$

41

 

 

$

22

 

 

$

112

 

 

$

83

 

By-product sales

 

 

19

 

 

 

12

 

 

 

54

 

 

 

46

 

Other

 

 

6

 

 

 

4

 

 

 

(4

)

 

 

2

 

Total

 

$

66

 

 

$

38

 

 

$

162

 

 

$

131

 

21


 

 

 

(3)

Consolidated Total Income (loss) before income taxes reconciles to Income (loss) before income taxes and equity in earnings of affiliated companies on the Consolidated Statements of Operations. Income (loss) before income taxes that are categorized as Unallocated and Other includes:

 

 

Three Months Ended June 30

 

 

Nine Months Ended June 30

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

 

(In millions)

 

Interest expense

 

$

(12

)

 

$

(13

)

 

$

(37

)

 

$

(41

)

Certain items(a)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Indirect tax settlement credits (Note G)

 

 

12

 

 

 

 

 

 

12

 

 

 

3

 

Global restructuring activities (Note J)

 

 

(4

)

 

 

(3

)

 

 

(8

)

 

 

(16

)

Employee benefit plan settlement and other charges (Note D)

 

 

(1

)

 

 

(2

)

 

 

(6

)

 

 

(5

)

Acquisition and integration-related charges

 

 

(2

)

 

 

(1

)

 

 

(4

)

 

 

(3

)

Legal and environmental matters and reserves

 

 

 

 

 

(1

)

 

 

 

 

 

(51

)

Specialty Fluids loss on sale and asset impairment charges

 

 

 

 

 

 

 

 

 

 

 

(1

)

Other

 

 

 

 

 

 

 

 

(1

)

 

 

(1

)

Total certain items, pre-tax

 

 

5

 

 

 

(7

)

 

 

(7

)

 

 

(74

)

Unallocated corporate costs(b)

 

 

(14

)

 

 

(10

)

 

 

(43

)

 

 

(32

)

General unallocated income (expense)(c)

 

 

1

 

 

 

2

 

 

 

(4

)

 

 

1

 

Less: Equity in earnings of affiliated companies, net

   of tax(d)

 

 

2

 

 

 

1

 

 

 

3

 

 

 

2

 

Total

 

$

(22

)

 

$

(29

)

 

$

(94

)

 

$

(148

)

 

 

(a)

Certain items are items of expense and income that management does not consider representative of the Company’s fundamental on-going segment results and they are, therefore, excluded from Segment EBIT.

 

(b)

Unallocated corporate costs are costs that are not controlled by the segments and primarily benefit corporate interests.

 

(c)

General unallocated income (expense) consists of gains (losses) arising from foreign currency transactions, net of other foreign currency risk management activities, Interest and dividend income, the profit or loss related to the corporate adjustment for unearned revenue, the impact of including the full operating results of a contractual joint venture in Purification Solutions Segment EBIT and unrealized holding gains (losses) for equity securities.

 

(d)

Equity in earnings of affiliated companies, net of tax, is included in Segment EBIT and is removed in Unallocated and other to reconcile to Income (loss) from operations before income taxes and equity in earnings from affiliated companies.

The Company’s segments operate globally. In addition to presenting Revenue from external customers by reportable segment, the following tables further disaggregate Revenues from external customers by geographic region.

 

 

Three Months Ended June 30, 2021

 

 

 

Reinforcement

Materials

 

 

Performance

Chemicals

 

 

Purification

Solutions

 

 

Consolidated Total

 

 

 

(In millions)

 

Americas

 

$

189

 

 

$

85

 

 

$

28

 

 

$

302

 

Asia Pacific

 

 

197

 

 

 

118

 

 

 

9

 

 

 

324

 

Europe, Middle East and Africa

 

 

93

 

 

 

100

 

 

 

32

 

 

 

225

 

Segment revenues from external customers

 

 

479

 

 

 

303

 

 

 

69

 

 

 

851

 

Unallocated and other

 

 

 

 

 

 

 

 

 

 

 

 

 

 

66

 

Net sales and other operating revenues

 

 

 

 

 

 

 

 

 

 

 

 

 

$

917

 

22


 

 

 

 

 

Three Months Ended June 30, 2020

 

 

 

Reinforcement

Materials

 

 

Performance

Chemicals

 

 

Purification

Solutions

 

 

Consolidated Total

 

 

 

(In millions)

 

Americas

 

$

59

 

 

$

54

 

 

$

28

 

 

$

141

 

Asia Pacific

 

 

106

 

 

 

98

 

 

 

8

 

 

 

212

 

Europe, Middle East and Africa

 

 

32

 

 

 

68

 

 

 

27

 

 

 

127

 

Segment revenues from external customers

 

 

197

 

 

 

220

 

 

 

63

 

 

 

480

 

Unallocated and other

 

 

 

 

 

 

 

 

 

 

 

 

 

 

38

 

Net sales and other operating revenues

 

 

 

 

 

 

 

 

 

 

 

 

 

$

518

 

 

 

 

Nine Months Ended June 30, 2021

 

 

 

Reinforcement

Materials

 

 

Performance

Chemicals

 

 

Purification

Solutions

 

 

Consolidated Total

 

 

 

(In millions)

 

Americas

 

$

501

 

 

$

232

 

 

$

79

 

 

$

812

 

Asia Pacific

 

 

537

 

 

 

358

 

 

 

27

 

 

 

922

 

Europe, Middle East and Africa

 

 

250

 

 

 

274

 

 

 

85

 

 

 

609

 

Segment revenues from external customers

 

 

1,288

 

 

 

864

 

 

 

191

 

 

 

2,343

 

Unallocated and other

 

 

 

 

 

 

 

 

 

 

 

 

 

 

162

 

Net sales and other operating revenues

 

 

 

 

 

 

 

 

 

 

 

 

 

$

2,505

 

 

 

 

 

 

Nine Months Ended June 30, 2020

 

 

 

Reinforcement

Materials

 

 

Performance

Chemicals

 

 

Purification

Solutions

 

 

Consolidated Total

 

 

 

(In millions)

 

Americas

 

$

354

 

 

$

206

 

 

$

83

 

 

$

643

 

Asia Pacific

 

 

398

 

 

 

271

 

 

 

26

 

 

 

695

 

Europe, Middle East and Africa

 

 

179

 

 

 

230

 

 

 

77

 

 

 

486

 

Segment revenues from external customers

 

 

931

 

 

 

707

 

 

 

186

 

 

 

1,824

 

Unallocated and other

 

 

 

 

 

 

 

 

 

 

 

 

 

 

131

 

Net sales and other operating revenues

 

 

 

 

 

 

 

 

 

 

 

 

 

$

1,955

 

 

N. Subsequent Events

In July 2021, the Company’s Specialty Compounds manufacturing and research and development facility in Pepinster, Belgium experienced significant flooding. The Company continues to assess the impact of the flooding on ongoing operations at the plant and is working with its insurance carriers to assess the amount of damage to equipment and inventory. It is anticipated that the plant will not be able to produce product for at least the remainder of fiscal year 2021. The Company currently estimates that a charge for the damages will be in a range of $10 million to $15 million. The Company anticipates that it may be able to recover a substantial portion of the losses from insurance proceeds, however, the amount and timing of any insurance recovery is not certain at this time.

Effective August 6, 2021, the Company entered into a new corporate revolving credit agreement (the “2021 Credit Agreement”), and terminated its existing corporate revolving credit agreement, which was scheduled to mature on October 23, 2022. The borrowing capacity under the 2021 Credit Agreement, which matures on August 6, 2026, subject to two one-year options to extend the maturity, exercisable prior to the first and second anniversaries of the effective date of the 2021 Credit Agreement, is $1 billion. The 2021 Credit Agreement supports the Company’s issuance of commercial paper, and borrowings under it may be used for working capital, letters of credit and other general corporate purposes.  The Credit Agreement contains affirmative and negative covenants, a financial leverage test requiring the ratio of net debt (with the ability to offset such debt by the lesser of (i) unrestricted cash and cash equivalents and (ii) $150 million) to consolidated EBITDA not to exceed 3.50 to 1.00, and annual sustainability performance targets related to the Company’s reduction in its nitrogen oxide and sulfur dioxide emissions intensity, the achievement of which may adjust pricing under the Credit Agreement.

23


 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Critical Accounting Policies

Our critical accounting policies have not substantially changed from those described in the 2020 10-K.

Recently Issued Accounting Pronouncements

Refer to the discussion under the headings “Recently Adopted Accounting Standards” and “Recent Accounting Pronouncements” in Note B of our Notes to the Consolidated Financial Statements.

 

 

Results of Operations

Cabot is organized into three reportable business segments: Reinforcement Materials, Performance Chemicals, and Purification Solutions. Cabot is also organized for operational purposes into three geographic regions: the Americas; Europe, Middle East and Africa; and Asia Pacific. The discussion of our results of operations for the periods presented reflects these structures.

Our analysis of our financial condition and operating results should be read with our consolidated financial statements and accompanying notes.

Definition of Terms and Non-GAAP Financial Measures

When discussing our results of operations, we use several terms as described below.

The term “product mix” refers to the mix of types and grades of products sold or the mix of geographic regions where products are sold, and the positive or negative impact this has on the revenue or profitability of the business and/or segment.

Our discussion under the heading “(Provision) Benefit for Income Taxes and Reconciliation of Effective Tax Rate to Operating Tax Rate” includes a discussion and reconciliation of our “effective tax rate” and our “operating tax rate” for the periods presented, as well as management’s projection of our operating tax rate range for the full fiscal year. Our operating tax rate is a non-GAAP financial measure and should not be considered as an alternative to our effective tax rate, the most comparable GAAP financial measure. The operating tax rate is calculated based upon management's forecast of the annual operating tax rate for the fiscal year applied to adjusted pre-tax earnings. The operating tax rate excludes income tax (expense) benefit on certain items, discrete tax items and, on a quarterly basis the timing of losses in certain jurisdictions. The income tax (expense) benefit on certain items is determined using the applicable rates in the taxing jurisdictions in which the certain items occurred and includes both current and deferred income tax (expense) benefit based on the nature of the certain items. Discrete tax items include, but are not limited to, changes in valuation allowance, uncertain tax positions, and other tax items, such as the tax impact of legislative changes. Our definition of the operating tax rate may not be comparable to the definition used by other companies. Management believes that this non-GAAP financial measure is useful supplemental information because it helps our investors compare our tax rate year to year on a consistent basis and to understand what our tax rate on current operations would be without the impact of these items.

Our discussion under the heading “Third Quarter of Fiscal 2021 versus Third Quarter Fiscal 2020—By Business Segment” includes a discussion of Total segment EBIT, which is a non-GAAP financial measure defined as Income (loss) before income taxes and equity in earnings from affiliated companies less certain items and other unallocated items. Our Chief Operating Decision Maker, who is our President and Chief Executive Officer, uses segment EBIT to evaluate the operating results of each segment and to allocate resources to the segments. We believe Total segment EBIT, which reflects the sum of EBIT from our reportable segments, provides useful supplemental information for our investors as it is an important indicator of our operational strength and performance, allows investors to see our results through the eyes of management, and provides context for our discussion of individual business segment performance. Our definition of Total segment EBIT may not be comparable to the definition used by other companies and it should not be considered an alternative for Income (loss) before income taxes and equity in earnings of affiliated companies, which is the most directly comparable GAAP financial measure. A reconciliation of Total segment EBIT to Income (loss) before income taxes and equity in earnings of affiliated companies is provided under the heading “Third quarter of Fiscal 2021 versus Third quarter of Fiscal 2020—By Business Segment”. Investors should consider the limitations associated with this non-GAAP measure, including the potential lack of comparability of this measure from one company to another.

24


 

In calculating Total segment EBIT, we exclude from our Income (loss) before income taxes and equity in earnings of affiliated companies (i) items of expense and income that management does not consider representative of our fundamental on-going segment results, which we refer to as “certain items”, and (ii) items that, because they are not controlled by the business segments and primarily benefit corporate objectives, are not allocated to our business segments, such as interest expense and other corporate costs, which include unallocated corporate overhead expenses such as certain corporate salaries and headquarter expenses, plus costs related to special projects and initiatives, which we refer to as “other unallocated items”. Management believes excluding the items identified as certain items facilitates operating performance comparisons from period to period by eliminating differences caused by the existence and timing of certain expense and income items that would not otherwise be apparent on a GAAP basis and also facilitates an evaluation of our operating performance without the impact of these costs or benefits. The items of income and expense that we exclude from Total segment EBIT but that are included in our GAAP Income (loss) before income taxes and equity in earnings of affiliated companies, as applicable in a particular reporting period, include, but are not limited to, the following:

 

Global restructuring activities, which include costs or benefits associated with cost reduction initiatives or plant closures and are primarily related to (i) employee termination costs, (ii) asset impairment charges associated with restructuring actions, (iii) costs to close facilities, including environmental costs and contract termination penalties and (iv) gains realized on the sale of land or equipment associated with restructured plants or locations.

 

Non-recurring gains (losses) on foreign exchange, which primarily relate to the impact of controlled currency devaluations on our net monetary assets denominated in that currency.

 

Legal and environmental matters and reserves, which consist of costs or benefits for matters typically related to former businesses or that are otherwise incurred outside of the ordinary course of business.

 

Executive transition costs, which include incremental charges, including stock compensation charges, associated with the retirement or termination of employment of senior executives of the Company.

 

Asset impairment charges, which primarily include charges associated with an impairment of goodwill or other long-lived assets.

 

Acquisition and integration-related charges, which include transaction costs, redundant costs incurred during the period of integration, and costs associated with transitioning certain management and business processes to our processes.

 

Gains (losses) on sale of investments, which primarily relate to the sale of investments accounted for using the cost method.

 

Inventory reserve adjustment, which generally result from an evaluation performed as part of an impairment analysis.

 

Indirect tax settlement credits, which includes favorable settlements resulting in the recoveries of indirect taxes.

 

Gains (losses) on sale of businesses.

 

Employee benefit plan settlements, which consist of either charges or benefits associated with the termination of a pension plan or the transfer of a pension plan to a multi-employer plan.

Overview

Our business, results of operations and cash flows in fiscal 2020 were adversely affected by the COVID-19 pandemic and its impact on our customers and our operations, predominately in the second and third fiscal quarters. As our customers in China began to restart operations at the end of March 2020, and in the Americas and Europe in May and June 2020, demand for our products began to improve. This recovery continued into the fourth quarter of fiscal 2020. We have continued to see strengthening of demand in the first nine months of fiscal 2021 as the recovery from COVID-19 continues, and fiscal year-to-date volumes in our Reinforcement Materials segment and our Performance Chemicals segment have returned to pre-COVID levels.

Despite this improvement in demand for our products, the duration and scope of the COVID-19 pandemic continues to be uncertain. Infection rates remain high in many parts of the world, and the virulence and spread of different strains of the virus and the level and timing of COVID-19 vaccine distribution across the world will impact the economic recovery and growth and the general economic consequences of the pandemic. In addition, the COVID-19 pandemic and other factors are having a negative impact on the cost and availability of global transportation and the availability of semi-conductor chips for the automotive industry. If these global logistics challenges or the semi-conductor chip shortage persist or intensify, they could negatively impact our results, particularly in our Performance Chemicals segment. Further, the COVID-19 pandemic has also contributed to increased costs and decreased availability of labor and materials for construction projects, and these factors may increase the costs of our capital improvement projects and delay our completion of such projects.  

25


 

If there is a resurgence in the COVID-19 pandemic impacting our business, it could cause us to recognize write-downs or impairments for certain assets, or a reduction in our borrowing availability under our credit agreements.  These factors could also result in an adverse impact on our revenue as well as our overall profitability.

During the third quarter of fiscal 2021, Income (loss) before income taxes and equity in earnings of affiliated companies increased compared to the third quarter of fiscal 2020. The increase is driven by the increase in Total segment EBIT of $127 million. The increase in Total segment EBIT was driven by higher volumes in all segments and higher unit margins in the Reinforcement Materials and Performance Chemicals segments.

Third quarter of Fiscal 2021 versus Third quarter of Fiscal 2020—Consolidated

Net Sales and Other Operating Revenues and Gross Profit

 

 

 

Three Months Ended June 30

 

 

Nine Months Ended June 30

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

 

(In millions)

 

Net sales and other operating revenues

 

$

917

 

 

$

518

 

 

$

2,505

 

 

$

1,955

 

Gross profit

 

$

214

 

 

$

69

 

 

$

621

 

 

$

363

 

 

The $399 million increase in net sales and other operating revenues in the third quarter of fiscal 2021 compared to the third quarter of fiscal 2020 was driven by higher volumes ($185 million), favorable price and product mix (combined $152 million) and favorable impact from foreign currency translation ($35 million) across all segments. The higher volumes in fiscal 2021 were driven by stronger demand across all regions as compared to lower volumes in fiscal 2020 primarily due to demand declines resulting from the COVID-19 pandemic. The favorable price and product mix was driven by higher prices from higher feedstock costs that are generally passed through to our customers in the Reinforcement Materials segment and favorable price and product mix in the Performance Chemicals segment driven by higher sales into automotive applications and targeted growth initiatives and price increases to recover rising raw material and other costs.

The $550 million increase in net sales and other operating revenues in the first nine months of fiscal 2021 compared to the first nine months of fiscal 2020 was driven by higher volumes ($318 million) in the Reinforcement Materials and Performance Chemicals segments, favorable price and product mix (combined $141 million), and favorable impact from foreign currency translation ($67 million) across all segments. The higher volumes in fiscal 2021 were driven by stronger demand across all regions as compared to lower volumes in fiscal 2020 due to demand declines resulting from the COVID-19 pandemic. The favorable price and product mix was due to improved product mix in all regions and higher prices from higher feedstock costs that are generally passed through to our customers in the Reinforcement Materials segment. Favorable price and product mix in the Performance Chemicals segment was driven by higher sales into automotive applications and targeted growth initiatives and price increases to recover rising raw material and other costs.

Gross profit increased by $145 million in the third quarter of fiscal 2021 compared to the third quarter of fiscal 2020. Gross profit increased by $258 million in the first nine months of fiscal 2021 compared to the first nine months of fiscal 2020. The gross profit increase in both comparative periods was primarily due to higher volumes and unit margins in the Reinforcement Materials and Performance Chemicals segments.

 

Selling and Administrative Expenses

 

 

 

Three Months Ended June 30

 

 

Nine Months Ended June 30

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

 

(In millions)

 

Selling and administrative expenses

 

$

68

 

 

$

52

 

 

$

200

 

 

$

230

 

 

Selling and administrative expenses increased by $16 million in the third quarter of fiscal 2021 compared to the same period of fiscal 2020, primarily due to increased incentive compensation. Selling and administrative expense decreased by $30 million in the first nine months of fiscal 2021 compared to the same period of fiscal 2020, primarily due to a $50 million legal settlement recorded during the second quarter of fiscal 2020. The decrease was partially offset by increased incentive compensation.

Research and Technical Expenses

 

 

 

Three Months Ended June 30

 

 

Nine Months Ended June 30

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

 

(In millions)

 

Research and technical expenses

 

$

12

 

 

$

13

 

 

$

41

 

 

$

41

 

26


 

 

 

Research and technical expenses decreased by $1 million in the third quarter of fiscal 2021 compared to the same period of fiscal 2020, and remained flat in the first nine months of fiscal 2021 compared to the same period of fiscal 2020.

Interest and Dividend Income, Interest Expense and Other Income (Expense)

 

 

 

Three Months Ended June 30

 

 

Nine Months Ended June 30

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

 

(In millions)

 

Interest and dividend income

 

$

2

 

 

$

1

 

 

$

6

 

 

$

7

 

Interest expense

 

$

(12

)

 

$

(13

)

 

$

(37

)

 

$

(41

)

Other income (expense)

 

$

(1

)

 

$

(3

)

 

$

(9

)

 

$

(6

)

 

Interest and dividend income increased $1 million in the third quarter of fiscal 2021 compared to the same period of fiscal 2020, primarily due to increased interest rates. For the nine months ended June 30, 2021, Interest and dividend income decreased $1 million primarily due to lower interest rates.

Interest expense decreased $1 million and $4 million in the third quarter of fiscal 2021 and for the nine months ended June 30, 2021, respectively, as compared to the same periods of fiscal 2020, primarily due to lower interest rates and reduction in debt.

Other income (expense) changed by $2 million in the third quarter of fiscal 2021 compared to the same period of fiscal 2020, primarily due to a favorable comparison of the impact from foreign currency translation. For the nine months ended June 30, 2021, Other income (expense) changed by $3 million compared to the same period of fiscal 2020. The change was primarily due to higher pension benefits in fiscal 2020 as a result of the termination of the U.S. pension plan.

(Provision) Benefit for Income Taxes and Reconciliation of Effective Tax Rate to Operating Tax Rate

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended June 30

 

2021

 

 

2020

 

 

 

(Provision) / Benefit for Income Taxes

 

Rate

 

 

(Provision) / Benefit for Income Taxes

 

Rate

 

Dollars in millions (unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Effective tax rate

 

$

(30

)

 

24

%

 

$

5

 

 

51

%

Less: Non-GAAP tax adjustments(1)

 

 

2

 

 

 

 

 

 

4

 

 

 

 

Operating tax rate

 

$

(32

)

 

27

%

 

$

1

 

 

29

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended June 30

 

2021

 

 

2020

 

 

 

(Provision) / Benefit for Income Taxes

 

Rate

 

 

(Provision) / Benefit for Income Taxes

 

Rate

 

Dollars in millions (unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Effective tax rate

 

$

(93

)

 

27

%

 

$

(9

)

 

17

%

Less: Non-GAAP tax adjustments(1)

 

 

3

 

 

 

 

 

 

27

 

 

 

 

Operating tax rate

 

$

(96

)

 

28

%

 

$

(36

)

 

29

%

 

(1)

Non-GAAP tax adjustments made to arrive at the operating tax provision include the income tax (expense) benefit on certain items, discrete tax items, and, on a quarterly basis the timing of losses in certain jurisdictions, as further described above under the heading “Definition of Terms and Non-GAAP Financial Measures”.

27


 

For the three months ended June 30, 2021, the (Provision) benefit for income taxes was a $30 million expense compared to a $5 million benefit for the same period in 2020. For the nine months ended June 30, 2021 the (Provision) benefit for income taxes was a $93 million expense compared to a $9 million expense for the same period in 2020. Our income taxes are affected by the mix of earnings in the tax jurisdictions in which we operate, and are impacted by the presence of valuation allowances in certain tax jurisdictions.

For fiscal year 2021, the Operating tax rate is expected to be in the range of 27% to 28%. We are not providing a forward-looking reconciliation of the operating tax rate range with an effective tax rate range because, without unreasonable effort, we are unable to predict with reasonable certainty the matters we would allocate to “certain items,” including unusual gains and losses, costs associated with future restructurings, acquisition-related expenses and litigation outcomes. These items are uncertain, depend on various factors, and could have a material impact on the effective tax rate in future periods.

Net Income (Loss) Attributable to Noncontrolling Interests

 

 

 

Three Months Ended June 30

 

 

Nine Months Ended June 30

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

 

(In millions)

 

Equity in earnings of affiliated companies,

   net of tax

 

$

2

 

 

$

1

 

 

$

3

 

 

$

2

 

Net income (loss) attributable to

   noncontrolling interests, net of tax

 

$

9

 

 

$

1

 

 

$

29

 

 

$

10

 

 

Equity in earnings of affiliated companies, net of tax, increased by $1 million in both the third quarter and first nine months of 2021 compared to the same periods of fiscal 2020.

Net income (loss) attributable to noncontrolling interests, net of tax, increased by $8 million and $19 million in the third quarter of fiscal 2021 and for the nine months ended June 30, 2021, respectively, as compared to the same periods in fiscal 2020 primarily due to higher profitability from our joint ventures in China and Czech Republic.

Net Income Attributable to Cabot Corporation

In the third quarter and first nine months of fiscal 2021, we reported Net income (loss) attributable to Cabot Corporation of $86 million and $221 million, or $1.48 per diluted common share and $3.84 per diluted common share, respectively. This compares to Net income (loss) attributable to Cabot Corporation of $(6) million and $34 million, or $(0.12) per diluted common share and $0.59 per diluted common share, respectively, in the third quarter and first nine months of fiscal 2020. The higher net income in the third quarter of fiscal 2021 and first nine months of fiscal 2021 compared with the same periods in fiscal 2020 was due to improved EBIT across all segments. In addition, the second quarter of fiscal 2020 included a $50 million charge related to a legal settlement.

Third quarter of Fiscal 2021 versus Third quarter of Fiscal 2020—By Business Segment

Income (loss) before income taxes and equity in earnings of affiliated companies, certain items, other unallocated items, and Total segment EBIT for the three and nine months ended June 30, 2021 and 2020 are set forth in the table below. The details of certain items and other unallocated items are shown below and in Note M of our Notes to the Consolidated Financial Statements.

 

 

 

Three Months Ended June 30

 

 

Nine Months Ended June 30

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

 

(In millions)

 

Income (loss) before income taxes and

   equity in earnings of affiliated companies

 

$

123

 

 

$

(11

)

 

$

340

 

 

$

51

 

Less: Certain items

 

 

5

 

 

 

(7

)

 

 

(7

)

 

 

(74

)

Less: Other unallocated items

 

 

(27

)

 

 

(22

)

 

 

(87

)

 

 

(74

)

Total segment EBIT

 

$

145

 

 

$

18

 

 

$

434

 

 

$

199

 

 

In the third quarter of fiscal 2021, Income (loss) before income taxes and equity in earnings of affiliated companies increased by $134 million and Total segment EBIT increased by $127 million. The increase in Income (loss) before income taxes and equity earnings of affiliated companies was driven by increased Total segment EBIT. The increase in Total segment EBIT was driven by higher volumes and unit margins, partially offset by higher fixed costs in the Reinforcement Materials and Performance Chemicals segments. Higher volumes in the Reinforcement Materials ($56 million) and Performance Chemicals segments ($24 million) were driven by stronger demand across all regions and key end markets due to continued market recovery from the declines in the prior year driven by the COVID-19 pandemic. Higher unit margins in the Reinforcement Materials segment ($57 million) were primarily driven by improved pricing in Asia. Higher unit margins in the Performance Chemicals segment ($18 million) were largely due to favorable product mix due to higher demand in automotive applications and our targeted growth initiatives.

28


 

In the first nine months of fiscal 2021, Income (loss) before income taxes and equity in earnings of affiliated companies increased by $289 million and Total segment EBIT increased by $235 million. The increase in Income (loss) before income taxes and equity earnings of affiliated companies was driven by increased Total segment EBIT and a $50 million charge in the second quarter of fiscal 2020 related to a legal settlement. The increase in Total segment EBIT was driven by higher volumes and unit margins, partially offset by higher fixed costs in the Reinforcement Materials and Performance Chemicals segments. Higher volumes in the Reinforcement Materials ($95 million) and Performance Chemicals segments ($53 million) were driven by stronger demand across all regions due to continued market recovery from the declines in the prior year driven by the COVID-19 pandemic. Higher unit margins in the Reinforcement Materials segment ($83 million) were primarily driven by stronger pricing in Asia. Higher unit margins in the Performance Chemicals segment ($36 million) were largely due to favorable product mix in our specialty carbons, specialty compounds, and fumed metal oxides product lines.

Certain Items

Details of the certain items for the third quarter and first nine months of fiscal 2021 and fiscal 2020 are as follows:

 

 

 

Three Months Ended June 30

 

 

Nine Months Ended June 30

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

 

(In millions)

 

Indirect tax settlement credits (Note G)

 

$

12

 

 

$

-

 

 

$

12

 

 

$

3

 

Global restructuring activities (Note J)

 

 

(4

)

 

 

(3

)

 

 

(8

)

 

 

(16

)

Employee benefit plan settlement and other charges (Note D)

 

 

(1

)

 

 

(2

)

 

 

(6

)

 

 

(5

)

Acquisition and integration-related charges

 

 

(2

)

 

 

(1

)

 

 

(4

)

 

 

(3

)

Legal and environmental matters and reserves

 

 

 

 

 

(1

)

 

 

 

 

 

(51

)

Specialty Fluids loss on sale and asset impairment charges

 

 

 

 

 

 

 

 

 

 

 

(1

)

Other

 

 

 

 

 

 

 

 

(1

)

 

 

(1

)

Total certain items, pre-tax

 

 

5

 

 

 

(7

)

 

 

(7

)

 

 

(74

)

Non-GAAP tax adjustments

 

 

2

 

 

 

4

 

 

 

3

 

 

 

27

 

Total certain items, after tax

 

$

7

 

 

$

(3

)

 

$

(4

)

 

$

(47

)

 

Other Unallocated Items

 

 

 

Three Months Ended June 30

 

 

Nine Months Ended June 30

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

 

(In millions)

 

Interest expense

 

$

(12

)

 

$

(13

)

 

$

(37

)

 

$

(41

)

Unallocated corporate costs

 

 

(14

)

 

 

(10

)

 

 

(43

)

 

 

(32

)

General unallocated income (expense)

 

 

1

 

 

 

2

 

 

 

(4

)

 

 

1

 

Less: Equity in earnings of affiliated

   companies, net of tax

 

 

2

 

 

 

1

 

 

 

3

 

 

 

2

 

Total other unallocated items

 

$

(27

)

 

$

(22

)

 

$

(87

)

 

$

(74

)

 

A discussion of items that we refer to as “other unallocated items” can be found under the heading “Definition of Terms and Non-GAAP Financial Measures”. The balances of unallocated corporate costs are primarily comprised of expenditures related to managing a public company that are not allocated to the segments and corporate business development costs related to ongoing corporate projects. The balances of General unallocated income (expense) consist of gains (losses) arising from foreign currency transactions, net of other foreign currency risk management activities, the profit or loss related to the corporate adjustment for unearned revenue, and the impact of including the full operating results of a contractual joint venture in Purification Solutions segment EBIT.

Reinforcement Materials

Sales and EBIT for Reinforcement Materials for the third quarter and first nine months of fiscal 2021 and 2020 were as follows:

 

 

 

Three Months Ended June 30

 

 

Nine Months Ended June 30

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

 

(In millions)

 

Reinforcement Materials Sales

 

$

479

 

 

$

197

 

 

$

1,288

 

 

$

931

 

Reinforcement Materials EBIT

 

$

85

 

 

$

(5

)

 

$

262

 

 

$

103

 

 

29


 

 

Sales in Reinforcement Materials increased by $282 million in the third quarter of fiscal 2021 compared to the same period of fiscal 2020, primarily due to higher volumes ($139 million), a favorable price and product mix (combined $124 million), and a favorable impact from foreign currency translation ($18 million). The higher volumes in fiscal 2021 were driven by stronger demand across all regions as compared to lower volumes in fiscal 2020 due to demand declines resulting from the COVID-19 pandemic. The favorable price and product mix was primarily due to higher prices from higher feedstock costs that are generally passed through to our customers.

In the first nine months of fiscal 2021, sales in Reinforcement Materials increased by $357 million when compared to the first nine months of fiscal 2020. The increase was primarily due to higher volumes ($226 million), a favorable price and product mix (combined $106 million), and a favorable impact from foreign currency translation ($24 million). The higher volumes in fiscal 2021 were driven by stronger demand across all regions as compared to lower volumes in fiscal 2020 due to demand declines resulting from the COVID-19 pandemic. The favorable price and product mix was primarily due to higher prices from higher feedstock costs that are generally passed through to our customers.

EBIT in Reinforcement Materials in the third quarter of fiscal 2021 increased $90 million compared to the same period of fiscal 2020. During the third quarter of fiscal 2021, the segment had higher unit margins ($57 million) and 71% higher volumes ($56 million), partially offset by higher fixed costs ($23 million). The higher volumes in fiscal 2021 were driven by stronger demand across all regions as compared to lower volumes in fiscal 2020 due to demand declines resulting from the COVID-19 pandemic. The higher unit margins were driven by significantly higher volumes across all regions, strong pricing in Asia, and improved geographic mix. The higher fixed costs were primarily due to higher maintenance costs after deferrals in the prior year.

EBIT in Reinforcement Materials increased $159 million in the first nine months of fiscal 2021 compared to the same period of fiscal 2020. The increase was driven by higher volumes ($95 million), higher unit margins ($83 million), and a favorable impact from foreign currency translation ($5 million). These factors were partially offset by higher fixed costs ($24 million). The higher volumes in fiscal 2021 were driven by stronger demand across all regions as compared to lower volumes in fiscal 2020 due to demand declines resulting from the COVID-19 pandemic. The higher unit margins were driven by stronger pricing in Asia. The higher fixed costs were primarily due to higher maintenance costs after deferrals in the prior year.

As we look to the fourth quarter of the fiscal year, we expect demand in the Reinforcement Materials segment to remain strong. We are also anticipating an elevated level of fixed costs as compared to the third quarter due to the timing of maintenance activities and an unplanned plant outage at our Franklin, Louisiana plant, along with higher feedstock differentials.

Performance Chemicals

Sales and EBIT for Performance Chemicals for the third quarter and first nine months of fiscal 2021 and 2020 were as follows:

 

 

 

Three Months Ended June 30

 

 

Nine Months Ended June 30

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

 

(In millions)

 

Performance Additives Sales

 

$

208

 

 

$

151

 

 

$

595

 

 

$

489

 

Formulated Solutions Sales

 

 

95

 

 

 

69

 

 

 

269

 

 

 

218

 

Performance Chemicals Sales

 

$

303

 

 

$

220

 

 

$

864

 

 

$

707

 

Performance Chemicals EBIT

 

$

54

 

 

$

21

 

 

$

166

 

 

$

93

 

 

Sales in Performance Chemicals increased by $83 million in the third quarter of fiscal 2021 compared to the same period of fiscal 2020, primarily due to increased volumes ($43 million), favorable price and product mix (combined $27 million), and the favorable impact from foreign currency translation ($14 million). The higher volumes were primarily due to stronger demand across our key product lines. The favorable product mix was due to higher demand in automotive applications, as well as the execution of targeted growth initiatives across the segment.

In the first nine months of fiscal 2021, sales in Performance Chemicals increased $157 million when compared to the same period of fiscal 2020. The increase was primarily due to higher volumes ($92 million), the favorable impact from foreign currency translation ($35 million), and favorable price and product mix (combined $30 million). The higher volumes were primarily due to stronger demand across our key product lines and inventory replenishment by our customers. The favorable product mix was primarily due to higher demand in automotive applications.

EBIT in Performance Chemicals increased by $33 million in the third quarter of fiscal 2021 compared to the third quarter of fiscal 2020 primarily due to increased volumes ($24 million), and higher unit margins ($18 million), partially offset by higher fixed costs ($12 million). Increased volumes resulted from increased demand across key product lines. Favorable unit margins were driven by higher demand in automotive applications in our specialty carbons and specialty compounds product lines, as well as the execution of targeted growth initiatives across the segment. Increased fixed costs were driven by higher depreciation related to a new fumed metal oxides plant and higher maintenance costs after deferrals in the prior year.

EBIT in Performance Chemicals increased by $73 million in the first nine months of fiscal 2021 when compared to the same period of fiscal 2020 primarily due to increased volumes ($53 million), higher unit margins ($36 million), and a favorable impact from

30


 

foreign currency translation ($7 million), partially offset by higher fixed costs ($23 million). Higher volumes across all product lines resulted from continuing strength in demand and inventory replenishment by our customers. Favorable unit margins were driven by higher demand in automotive applications and in targeted growth initiatives. Increased fixed costs were driven by higher depreciation from the startup of our new fumed metal oxides plant, and higher maintenance costs after deferrals in the prior year.

As we look to the fourth quarter of the fiscal year, we anticipate demand in the Performance Chemicals segment to remain strong overall with some lower seasonal demand. However, we anticipate higher fixed costs due to timing of maintenance activities and unfavorable impacts related to unplanned plant outages at our Franklin, Louisiana and Pepinster, Belgium plants.

Purification Solutions

Sales and EBIT for Purification Solutions for the third quarter and first nine months of fiscal 2021 and 2020 were as follows:

 

 

 

Three Months Ended June 30

 

 

Nine Months Ended June 30

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

 

(In millions)

 

Purification Solutions Sales

 

$

69

 

 

$

63

 

 

$

191

 

 

$

186

 

Purification Solutions EBIT

 

$

6

 

 

$

2

 

 

$

6

 

 

$

3

 

 

Sales in Purification Solutions increased by $6 million in the third quarter of fiscal 2021 compared to the same period of fiscal 2020 due to higher volumes ($3 million) and favorable impact from foreign currency translation ($3 million). The higher volumes were primarily due to higher sales in specialty applications.

Sales in Purification Solutions increased by $5 million in the first nine months of fiscal 2021 when compared to the same period of fiscal 2020 due to the favorable impact from foreign currency translation ($8 million), and improved pricing and a more favorable product mix (combined $5 million), partially offset by lower volumes ($8 million). The lower volumes were primarily due to lower sales in mercury removal products.

EBIT in Purification Solutions increased by $4 million in the third quarter of fiscal 2021 compared to the third quarter of fiscal 2020 due to higher volumes ($2 million), and the receipt of insurance proceeds ($2 million). The higher volumes were primarily due to higher sales in specialty applications. The insurance proceeds were related to a plant outage that occurred in the first quarter of the fiscal year.  

EBIT in Purification Solutions increased by $3 million in the first nine months of fiscal 2021 when compared to the same period of fiscal 2020 due to reduction in fixed costs ($7 million), partially offset by lower volumes ($4 million). Reduction in fixed costs were driven by the sale of our mine in Marshall, TX and the related long-term activated carbon supply agreement. The lower volumes were primarily due to a decrease in sales of mercury removal applications.

As we look to the fourth quarter of the fiscal year in the Purification Solutions segment, we expect to see lower volumes in mercury removal applications and the insurance proceeds received in the third quarter will not repeat.

 

 

Cash Flows and Liquidity

Overview

Our liquidity position, as measured by cash and cash equivalents plus borrowing availability, decreased by $111 million during the first nine months of fiscal 2021, which was largely attributable to the termination of our $100 million unsecured revolving credit agreement (the “Canadian Credit Agreement”) in the second quarter of fiscal 2021. As of June 30, 2021, we had cash and cash equivalents of $173 million and borrowing availability under our revolving credit agreements of $1.2 billion.

As of June 30, 2021, we had access to borrowings under the following two credit agreements:

 

$1 billion unsecured revolving credit agreement (the “JPM Credit Agreement”) with JPMorgan Chase Bank, N.A., as Administrative Agent, Citibank, N.A., as Syndication Agent, and the other lenders party thereto. The JPM Credit Agreement provided liquidity for working capital and general corporate purposes and supports our commercial paper program. As described below, the JPM Credit Agreement was terminated effective August 6, 2021, when the Company entered into a new revolving credit agreement.

 

€300 million unsecured revolving credit agreement (the “Euro Credit Agreement” and together with the JPM Credit Agreement, the “Credit Agreements”), with Wells Fargo Bank, National Association, as Administrative Agent, and the other lenders party thereto, which matures in May 2024 or earlier upon maturity of the JPM Credit Agreement. Borrowings under the Euro Credit Agreement may be used for the repatriation of earnings of our foreign subsidiaries to the United States, the repayment of indebtedness of our foreign subsidiaries owing to us or any of our subsidiaries and for working capital and general corporate purposes.

31


 

During the second quarter of 2021, we terminated our $100 million unsecured revolving credit agreement with TD Bank, NA, as Lender, which had a maturity date of September 2021. The Canadian Credit Agreement provided liquidity for working capital and general corporate purposes for certain of our Canadian subsidiaries. We had no borrowings under this agreement during either fiscal 2021 or 2020.

As of June 30, 2021, we were in compliance with our debt covenants under the Credit Agreements, which, with limited exceptions, generally require us to comply on a quarterly basis with a leverage test requiring consolidated total debt not to exceed consolidated EBITDA (earnings before interest, taxes, depreciation and amortization) for the four quarters then ending by more than 3.50 to 1.00. Because of the uncertainty of the overall financial impact of the COVID-19 pandemic and to increase our financial flexibility, we amended the Credit Agreements as of June 8, 2020 to, among other changes, set the consolidated total debt to consolidated EBITDA ratio at 4.50 to 1.00 for the fiscal quarters ending September 30, 2020 through June 30, 2021.

Effective August 6, 2021, we entered into a new corporate revolving credit agreement (the “2021 Credit Agreement”), and terminated our existing corporate revolving credit agreement, which was scheduled to mature on October 23, 2022.  The borrowing capacity under the 2021 Credit Agreement, which matures on August 6, 2026, subject to two one-year options to extend the maturity, exercisable on or prior to the first and second anniversaries of the effective date of the 2021 Credit Agreement, is $1 billion. The 2021 Credit Agreement supports our issuance of commercial paper, and borrowings under it may be used for working capital, letters of credit and other general corporate purposes. The Credit Agreement contains affirmative and negative covenants, a financial leverage test requiring the ratio of net debt (with the ability to offset such debt by the lesser of (i) unrestricted cash and cash equivalents and (ii) $150 million) to consolidated EBITDA not to exceed 3.50 to 1.00, and annual sustainability performance targets related to the Company’s reduction in its nitrogen oxide and sulfur dioxide emissions intensity, the achievement of which may adjust pricing under the Credit Agreement.

A significant portion of our business occurs outside the U.S. and our cash generation does not always align geographically with our cash needs. The vast majority of our cash and cash equivalent holdings tend to be held outside the U.S. Cash held by foreign subsidiaries is generally used to finance the subsidiaries’ operational activities and future investments. We are currently using a combination of commercial paper and revolving credit facility borrowings to meet our U.S. cash needs. We generally reduce our commercial paper balance and, if applicable, borrowings under our revolving credit facilities, at quarter-end using cash derived from customer collections, settlement of intercompany balances and short-term intercompany loans. If additional funds are needed in the U.S., we expect to be able to repatriate funds or to access additional debt under our revolving credit facilities. As of June 30, 2021, there were no borrowings on the JPM Credit Agreement. As of June 30, 2021, our borrowings under the Euro Credit Agreement totaled $140 million and we had $59 million of commercial paper outstanding.

We generally manage our cash and debt on a global basis to provide for working capital requirements as needed by region or site. Cash and debt are generally denominated in the local currency of the subsidiary holding the assets or liabilities, except where there are operational cash flow reasons to hold non-functional currency or debt.

We continue to actively manage the business throughout the ongoing COVID-19 pandemic to maintain cash flow and we anticipate sufficient liquidity from (i) cash on hand; (ii) cash flows from operating activities; and (iii) cash available from our revolving credit facilities and our commercial paper program to meet our operational and capital investment needs and financial obligations for the foreseeable future. The liquidity we derive from cash flows from operations is, to a large degree, predicated on our ability to collect our receivables in a timely manner, the cost of our raw materials, and our ability to manage inventory levels.

The following discussion of the changes in our cash balance refers to the various sections of our Consolidated Statements of Cash Flows.

Cash Flows from Operating Activities

Cash provided by operating activities, which consists of net income adjusted for the various non-cash items included in income, changes in working capital and changes in certain other balance sheet accounts, totaled $157 million in the first nine months of fiscal 2021 compared to $278 million of cash provided by operating activities during the same period of fiscal 2020.

Cash provided by operating activities in the first nine months of fiscal 2021 was driven by business earnings excluding the non-cash impact of depreciation and amortization of $117 million, which was partially offset by an increase in net working capital of $226 million. The increase in net working capital was driven by an increase in accounts receivable due to higher sales and an increase in inventory driven by a higher cost of raw materials, partially offset by an increase in accounts payable. Additionally, we made a cash payment of $32.6 million in the first quarter of fiscal 2021 related to a respirator litigation settlement in fiscal 2020 as discussed in Note G.

Cash provided by operating activities in the first nine months of fiscal 2020 was driven primarily by business earnings excluding the non-cash impact of depreciation and amortization of $117 million and a decrease in net working capital of $178 million, partially offset by an increase in Prepaid expenses and other assets of $25 million and a deferred tax benefit of $20 million.

32


 

In addition to the factors noted above, the following other elements of operations have a bearing on operating cash flows:

Restructurings — As of June 30, 2021, we had $8 million of total restructuring costs in accrued expenses in the Consolidated Balance Sheets related to certain of our global restructuring activities. In the first nine months of fiscal 2021, we paid $7 million related to these restructuring activities, and we expect to make additional cash payments of approximately $4 million in fiscal 2021 and $12 million thereafter.

Litigation Matters — As of June 30, 2021, we had a $20 million reserve for pending and future respirator claims that we expect to pay over multiple years. During fiscal 2020, we settled a large group of respirator claims for $65.2 million. We paid $32.6 million related to these settled claims during fiscal 2020, and the remaining $32.6 million in the first quarter of fiscal 2021. We also have other lawsuits, claims and contingent liabilities arising in the ordinary course of business.

Cash Flows from Investing Activities

Investing activities consumed $110 million of cash in the first nine months of fiscal 2021 compared to $252 million of cash consumed in the first nine months of fiscal 2020. In both periods, investing activities included capital expenditures for sustaining and compliance capital projects at our operating facilities as well as capacity expansion capital expenditures. In addition, in the first nine months of fiscal 2020 we paid $84 million, net of cash acquired, for the acquisition of Shenzhen Sanshun Nano New Materials Co., Ltd in April 2020 and $8 million for the plant that we acquired from Nippon Steel Carbon Co., Ltd in September 2018. In the first nine months of fiscal 2021, capacity expansion capital expenditures were primarily in Performance Chemicals, and in the same period of fiscal 2020 they were primarily in Performance Chemicals and Reinforcement Materials.

Capital expenditures for fiscal 2021 are expected to be approximately $200 million. Our planned capital spending program for fiscal 2021 is primarily for sustaining, compliance and improvement capital projects at our operating facilities as well as capacity expansion capital expenditures in Performance Chemicals.

Cash Flows from Financing Activities

Financing activities consumed $48 million of cash in the first nine months of fiscal 2021 compared to $37 million during the same period of fiscal 2020. In the first nine months of fiscal 2021, financing activities primarily consisted of dividend payments to stockholders of $60 million, dividend payments to noncontrolling interests of $20 million, and net repayments from borrowings under our revolvers of $15 million, which consisted of proceeds of $150 million less repayments of $165 million, partially offset by net proceeds from the issuance of commercial paper of $46 million.

In the first nine months of fiscal 2020, financing activities primarily consisted of dividend payments to stockholders of $60 million, share repurchases of $44 million, dividend payments to noncontrolling interests of $26 million, the repayment of $20 million of commercial paper and the repayment of $15 million of other long-term debt, partially offset by the net proceeds from borrowings under our revolvers of $125 million, which consisted of proceeds of $444 million less repayments of $319 million.

Off-Balance Sheet Arrangements

As of June 30, 2021, we had no material transactions that meet the definition of an off-balance sheet arrangement.

Forward-Looking Information

This report on Form 10-Q contains “forward-looking statements” under the Federal securities laws. These forward-looking statements address expectations or projections about the future, including our expectations for future financial performance and the factors we expect to impact our results of operations, including the factors we expect to impact results in our Reinforcement Materials, Performance Chemicals, and Purification Solutions segment in the fourth  quarter of fiscal 2021; the amount of a charge for the damages related to the flooding at our manufacturing and research and development facility in Pepinster, Belgium and the duration of the plant outage during which time we will not be able to produce product at this plant; the amount and timing of the charge to earnings we will record and the cash outlays we will make in connection with our reorganization and the closing of certain manufacturing facilities, restructuring initiatives and under our transformation plan for our Purification Solutions business; our estimated future amortization expenses for our intangible assets; the timing of expected payments from our reserve for pending and future respirator claims; our entry into cross-currency swaps and other financial instruments to manage foreign currency risks; the sufficiency of our cash on hand, cash provided from operations and cash available under our credit facilities and commercial paper program to fund our cash requirements; our expectations regarding our ability to repatriate funds or access additional debt under our revolving credit facilities; uses of available cash including anticipated capital spending; our expected operating tax rate for fiscal 2021; and the possible outcome of legal proceedings. From time to time, we also provide forward-looking statements in other materials we release to the public and in oral statements made by authorized officers.

33


 

Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, potentially inaccurate assumptions, and other factors, some of which are beyond our control or difficult to predict. If known or unknown risks materialize, our actual results could differ materially from those expressed in the forward-looking statements. Importantly, as we cannot predict the duration or scope of the COVID-19 pandemic, the negative impact to our results cannot be estimated with certainty. Factors that will influence the impact on our business and operations include the duration and extent of the pandemic, the virulence and spread of different strains of the virus and the level and timing of vaccine distribution around the world and their impact on the economic recovery and growth, the degree of disruption in our supply chain from global logistics matters resulting from the COVID-19 pandemic, and the general economic consequences of the pandemic. Further, the COVID-19 pandemic has also contributed to increased costs and decreased availability of labor and materials for construction projects, and these factors may increase the costs of our capital improvement projects and delay our completion of such projects.

In addition to factors described elsewhere in this report, the following are some of the factors that could cause our actual results to differ materially from those expressed in our forward-looking statements: industry capacity utilization and competition from other specialty chemical companies; safety, health and environmental requirements and related constraints imposed on our business; volatility in the price and availability of energy and raw materials; a significant adverse change in a customer relationship or the failure of a customer to perform its obligations under agreements with us; failure to achieve growth expectations from new products, applications and technology developments; failure to realize benefits from acquisitions, alliances, or joint ventures or achieve our portfolio management objectives; negative or uncertain worldwide or regional economic conditions and market opportunities, including from trade relations or global health matters; litigation or legal proceedings; tax rates and fluctuations in foreign currency exchange and interest rates; our inability to complete capacity expansions or other development projects; and the accuracy of the assumptions we used in establishing reserves for our share of liability for respirator claims. These other factors and risks are discussed more fully in our 2020 10-K and in our subsequent SEC filings.

 

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Information about market risks for the period ended June 30, 2021 does not differ materially from that discussed under Item 7A of our 2020 10-K.

Item 4.

Controls and Procedures

As of June 30, 2021, we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and our principal financial officer, of the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15 under the Securities Exchange Act of 1934, as amended. Based upon that evaluation, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were effective as of that date.

There were no changes in our internal controls over financial reporting that occurred during our fiscal quarter ended June 30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. As a result of the COVID-19 pandemic, certain of our employees have been working remotely and certain manufacturing sites have been operating with limited personnel on-site. We have not identified any material changes in our internal control over financial reporting as a result of these changes to the working environment. We are continually monitoring and assessing the COVID-19 situation to determine any potential impacts on the design and operating effectiveness of our internal controls over financial reporting.

 

34


 

 

Part II. Other Information

Item 5.

Other Information

On August 6, 2021, we entered into a $1 billion unsecured revolving credit agreement (the "Credit Agreement") with a syndicate of lenders arranged by JPMorgan Chase Bank, N.A., Lead Left Bookrunner, Administrative Agent and Joint Lead Arranger, Citibank, N.A., Joint Lead Bookrunner, Joint Lead Arranger and Syndication Agent, Mizuho Bank, LTD., TD Securities (USA) LLC, Bank of America, N.A., U.S. Bank, National Association as Joint Lead Arrangers and Co-Documentation Agents, and Wells Fargo Bank, National Association as Co-Documentation Agent. J.P. Morgan Securities LLC and Mizuho Bank, LTD. also served as Co-Sustainability Agents for the facility.

Borrowings under the Credit Agreement may be made in multiple currencies and used for commercial paper support, working capital, letters of credit and other general corporate purposes. The facility matures on August 6, 2026, subject to two options to extend the maturity by one year, exercisable prior to the first and second anniversaries of the date of the Credit Agreement. At the Company’s election, eurocurrency loans denominated in U.S. dollars will bear interest at the LIBOR rate plus an applicable margin of between 0.68% and 1.20%, depending on the Company’s credit ratings, and at similar applicable rates for foreign currency borrowings. Pricing is also based upon the Company’s performance against annual intensity reduction targets for its sulfur dioxide (SO2) and nitrogen oxide (NOX) emissions. The Credit Agreement requires the Company to comply on a quarterly basis with a leverage test requiring net debt (with the ability to offset such debt by the lesser of (i) unrestricted cash and cash equivalents and (ii) $150 million) not to exceed consolidated EBITDA for the four quarters then ending by more than 3.50 to 1.00. Consistent with the Company’s former $1 billion revolving credit agreement, the Credit Agreement also includes negative covenants limiting, subject to exceptions, the Company’s ability to incur liens and subsidiary indebtedness, among other customary restrictions, as well as customary representations and warranties, affirmative covenants and events of default, including cross defaults and a change of control default. This description is a summary and is qualified in its entirety by reference to the Credit Agreement, which is filed as Exhibit 10.1 to this Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2021.  

Concurrently with entering into the Credit Agreement, on August 6, 2021, we terminated our $1 billion revolving credit agreement with JPMorgan Chase Bank, N.A. and the other lenders party thereto, which, by its terms, was scheduled to mature on October 23, 2022.

35


 

Item 6.

Exhibits

 

Exhibit No.

 

Description

 

 

 

Exhibit 3.1

 

Restated Certificate of Incorporation of Cabot Corporation effective January 9, 2009 (incorporated herein by reference to Exhibit 3.1 of Cabot’s Quarterly Report on Form 10-Q for the quarterly period ended December 31, 2008, file reference 1-5667, filed with the SEC on February 9, 2009).

 

 

 

Exhibit 3.2

 

 

The By-laws of Cabot Corporation as amended January 7, 2021 (incorporated herein by reference to Exhibit 3.1 of Cabot Corporation’s Current Report on Form 8-K, file reference 1-5667, filed with the SEC on January 12, 2021).

 

 

 

Exhibit 10.1*

 

 

Credit Agreement, dated August 6, 2021, between Cabot Corporation, JPMorgan Chase Bank, N.A., J.P. Morgan Securities LLC, Citibank, N.A., Mizuho Bank, LTD., TD Bank, N.A., Bank of America, N.A., U.S. Bank, National Association, Wells Fargo Bank, National Association, and the other lenders party thereto.

 

Exhibit 31.1*

 

Certification of Principal Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act.

 

 

 

Exhibit 31.2*

 

Certification of Principal Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act.

 

 

 

Exhibit 32**

 

Certifications of the Principal Executive Officer and the Principal Financial Officer pursuant to 18 U.S.C. Section 1350.

 

 

 

Exhibit 101.INS*

 

Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

 

 

 

Exhibit 101.SCH*

 

Inline XBRL Taxonomy Extension Schema Document.

 

 

 

Exhibit 101.CAL*

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document.

 

 

 

Exhibit 101.DEF*

 

Inline XBRL Taxonomy Extension Definition Linkbase Document.

 

 

 

Exhibit 101.LAB*

 

Inline XBRL Taxonomy Extension Label Linkbase Document.

 

 

 

Exhibit 101.PRE*

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document.

 

 

 

Exhibit 104*

 

The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, formatted in Inline XBRL (included in Exhibit 101).

 

*

Filed herewith.

**

Furnished herewith.

36


 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

CABOT CORPORATION

 

 

 

 

Date: August 9, 2021

 

By:

/s/ Erica McLaughlin

 

 

 

Erica McLaughlin

 

 

 

Senior Vice President and Chief Financial Officer

 

 

 

(Duly Authorized Officer)

 

 

 

 

 

 

 

 

Date: August 9, 2021

 

By:

/s/ Lisa m. Dumont

 

 

 

Lisa M. Dumont

 

 

 

Vice President and Controller

(Chief Accounting Officer)

 

 

37